US20040006776A1 - Transgenic production of antibodies in milk - Google Patents
Transgenic production of antibodies in milk Download PDFInfo
- Publication number
- US20040006776A1 US20040006776A1 US09/012,904 US1290498A US2004006776A1 US 20040006776 A1 US20040006776 A1 US 20040006776A1 US 1290498 A US1290498 A US 1290498A US 2004006776 A1 US2004006776 A1 US 2004006776A1
- Authority
- US
- United States
- Prior art keywords
- immunoglobulin
- promoter
- dna
- mammal
- milk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
Definitions
- This invention pertains to a method for the production of monoclonal antibodies in mammal's milk, specifically through the creation of transgenic animals that selectively express foreign antibody genes in mammary epithelial cells.
- Immunoglobulins are heteropolymeric proteins that are normally synthesized, modified, assembled, and secreted from circulating B lymphocytes. Using recombinant DNA technology, it is possible to program cells other than B-lymphocytes to express immunoglobulin genes.
- immunoglobulin genes including their respective promoter regions
- lymphocytes and secretion into the bloodstream of the host animal necessitates a strategy for suppressing the expression of the host's endogenous immunoglobulins, and raises the problem of purifying the immunoglobulins from serum, which contains many other proteins, including proteolytic enzymes.
- heavy and light chain genes must both be incorporated into the host genome, in a manner that enables their comcomittant expression.
- TPA tissue plasminogen activator
- cystic fibrosis transmembrane conductance regulator DiTullio et al., Bio/Technology 10:74, 1992
- urokinase Meade et al., Bio/Technology 8: 443, 1990
- interleukin-2 Buhler et al., Bio/Technology 8:140, 1990
- antihemophilic factor IX Clark et al., Bio/Technology 7:487, 1989.
- these proteins are all simple single-chain polypeptides that do not require multimerization or assembly prior to secretion.
- Another object of the invention is to provide methods for the design of synthetic immunoglobulins that can be produced in large quantities in milk.
- Yet another object of the invention is to provide methods for administering therapeutically beneficial antibodies to suckling young, by creating female mammals that excrete such antibodies into their milk.
- a further object of the invention is a transgenic non-human mammal having germ and somatic cells with recombinant DNA sequences encoding immunoglobulin light and heavy chains, where said sequences are operatively linked at their 5′ termini to a mammary specific promoter and at their 3′ end to a sequence comprising a polyadenylation site.
- a further object of the invention is a casein promoter cassette comprising in the 5′ to 3′ direction:
- FIG. 1 is a schematic representation of the Bc62 plasmid, which contains a 13.9 kb Sal I fragment that comprises cDNA encoding immunoglobulin light chain, flanked on its 5′ and 3′ termini by goat beta casein sequences.
- FIG. 2 is a schematic representation of the Bc61 plasmid, which contains a 14.6 kb Sal I fragment that comprises cDNA encoding immunoglobulin heavy chain, flanked on its 5′ and 3′ termini by goat beta casein sequences.
- FIG. 3 depicts the immunoblot detection of human immunoglobulin heavy chain in the milk, of transgenic mice that were created using the beta casein promoter-linked immunoglobulin genes shown in FIGS. 1 and 2.
- FIG. 4 depicts the immunoblot detection of human immunoglobulin light chain in the milk of transgenic mice that were created using the beta casein promoter-linked immunoglobulin genes shown in FIGS. 1 and 2.
- this invention comprises a method for obtaining heterologous immunoglobulins from the milk of transgenic mammals.
- Another aspect of the prevent invention comprises the method for creating transgenic mammals by introducing into their germline immunoglobulin cDNA linked to a milk-specific promoter.
- the present invention comprises transgenic mammals having germ cells and somatic cells having recombinant DNA sequences comprising immunoglobulin cDNA linked to a milk-specific promoter.
- the present invention comprises an isolated DNA comprising an expression cassette having 5′ and 3′ non-coding sequences derived from the goat beta casein gene linked via a unique restriction site that serves as a convenient cloning site for immunoglobulin coding sequences.
- the present invention pertains to a method for the production of monoclonal antibodies that are excreted into the milk of transgenic animals and the method for production of such animals. This is achieved by engineering DNA construct's in which DNA segments encoding specific paired immunoglobulin heavy and preferentially expressed in mammary epithelial cells. The recombinant DNAs containing the promoter-linked heavy and light chain genes are then coinjected into preimplantation embryos. The a progeny are screened for the presence of both transgenes.
- the antibodies may be purified from the milk, or the milk itself, comprising the immunoglobulins, may be used to deliver the antibodies to a recipient. This is discussed below.
- the immunoglobulin genes useful in the present invention may be obtained from natural sources e.g. individual B cell clones or hybridomas derived therefrom. Alternately, they may comprise synthetic single-chain antibodies in which the light and heavy variable regions are expressed as part of a single polypeptide. Furthermore, recombinant antibody genes may be used that have been predictively altered by nucleotide substitutions that do or do not change the amino acid sequence, by addition or deletion of sequences, or by creation of hybrid genes in which different regions of the polypeptide are derived from different sources. Antibody genes by their nature are extremely diverse, and thus naturally tolerate a great deal of variation. It will be appreciated by those skilled in the art that the only limitation for producing an antibody by the method of the present invention is that it must assemble into a functional configuration and be secreted in a stable form into the milk.
- the transcriptional promoters useful in practicing the present invention are those promoters that are preferentially activated in mammary epithelial cells, including promoters that control the genes encoding milk proteins such as caseins, beta lactoglobulin (Clark et al., (1989) Bio/Technolog 7: 487-492), whey acid protein (Gordon et al., (1987) Bio/Technology 5: 1183-1187 ), and lactalbumin (Soulier et al., (1992) FEBS Letts.
- milk proteins such as caseins, beta lactoglobulin (Clark et al., (1989) Bio/Technolog 7: 487-492), whey acid protein (Gordon et al., (1987) Bio/Technology 5: 1183-1187 ), and lactalbumin (Soulier et al., (1992) FEBS Letts.
- Casein promoters may be derived from the alpha, beta, or kappa casein genes of any mammalian species; a preferred promoter is derived from the goat beta casein gene (DiTullio, (1992) Bio/Technology 10:74-77).
- a unique XhoI restriction site is introduced at the 3′ terminus of the promoter sequence to allow the routine insertion of immunoglobulin coding sequences.
- the inserted immunoglobulin gene is flanked on its 3′ side by cognate genomic sequences from a mammary-specific gene, to provide a polyadenylation site and transcript-stabilizing sequences. Transcription of the construct in vivo results in the production of a stable mRNA containing casein-derived 5′ untranslated sequences upstream of the translational initiator codon of the immunoglobulin gene and 3′ untranslated sequences downstream of the translational termination codon of the immunoglobulin gene. Finally, the entire cassette (i.e.
- promoter-immunoglobulin-3′ region is flanked by restriction sites that enable the promoter-cDNA cassette to be easily excised as a single fragment. This facilitates the removal of unwanted prokaryotic vector-derived DNA sequences prior to injection into fertilized eggs.
- the promoter-linked immunoglobulin heavy and light chain DNAs are then introduced into the germ line of a mammal e.g. cow, sheep, goat, mouse, oxen, camel or pig. Mammals are defined herein as all animals, excluding humans, that have mammary glands and produce milk. Mammalian species that produce milk in large amounts over long periods of time are preferred.
- the DNA is injected into the pronuclei of fertilized eggs, which are then implanted into the uterus of a recipient female and allowed to gestate.
- the putative transgenic animals are tested for the presence of the introduced DNA This is easily achieved by Southern blot hybridization of DNA extracted from blood cells or other available tissue, using as a probe a segment of the injected gene that shows no cross hybridization with the DNA of the recipient species. Progeny that show evidence of at least one copy of both heavy and light-chain immunoglobulin genes are selected for further analysis.
- Transgenic females may be tested for immunoglobulin secretion into milk, using any of the immunological techniques that are standard in the art (e.g. Western blot, radioimmunoassay, ELISA)
- the anti-immunoglobulin antibodies used in this analysis may be polyclonal or monoclonal antibodies that detect isolated heavy or light chains or others that react only with fully assembled (H2L2) immunoglobulins.
- the recombinant immunoglobulins are also characterized with respect to their functionality, i.e. binding specificity and affinity for a particular antigen. This is achieved using immunological methods that are standard in the art, such as Scatchard analysis, binding to immobilized antigen., etc.
- the stability characteristics of an immunoglobulin in the milk of a given species are also assayed, by applying the above-described detection methods to milk that has been incubated for increasing times after recovery from the animal.
- the immunoglobulins produced by the methods of the present invention may be purified from milk, using adsorption to immobilized Protein G, column chromatography, and other methods known to those of ordinary skill in the art of antibody purification.
- the level of production of recombinant immunoglobulins in is an individual transgenic mammal is primarily determined by the site and manner of integration of the transgene after injection into the fertilized egg. Thus, transgenic progeny derived from different injected eggs may vary with respect to this parameter. The amount of recombinant immunoglobulin in milk is therefore monitored in representative progeny, and the highest-producing females are preferred.
- the present invention encompasses high-level expression of antibodies that are harvested and purified from milk and used in purified form. High-level expression is defined herein as the production of about 1 mg/ml of protein.
- antibodies are engineered that provide protection to humans against infectious diseases; therapeutic administration is then achieved by drinking the milk.
- lactating animals are engineered to produce antibodies specifically beneficial to their offspring, which acquire them through suckling.
- animals produce an antibody that protects the lactating mammal itself against breast pathogens e.g. bacteria that produce mastitis.
- the unexpectedly high-volume expression of immunoglobulins using the method and constructs of the present invention also allows the use of such immunoglobulins in pharmaceutical and chemical settings.
- the method of the present invention can be used to produce high levels of tetrameric antibodies directed against various pathogens (e.g. E. coli, Salmonella, hepatitis B virus), biologically active peptides (e.g. erythropoietin, tissue plasminogen activator, gamma interferon) and for use in chemical reactions directed against various enzymes.
- pathogens e.g. E. coli, Salmonella, hepatitis B virus
- biologically active peptides e.g. erythropoietin, tissue plasminogen activator, gamma interferon
- Monoclonal antibodies that bind to the transition state of a chemical reaction can be used in industrial-scale production.
- monoclonal antibodies are often immobilized on columns for use in the purification of biopharmaceuticals; in such cases, production of the antibodies represents a significant fraction of the cost of purification.
- the methods of the present invention -facilitate the production of high volume, low cost antibody stocks for use in these types of applications.
- the present invention encompasses a recipient vector into which many different immunoglobulin genes can be interchangeably inserted.
- the vector contains 5′ milk-specific promoter sequences and 3′ untranslated genomic sequences that flank an XhoI cloning site. This cloning is unique because it is the only one present in the vector.
- the entire expression cassette should be flanked by restriction sites that allow the easy excision of the promoter-linked immunoglobulin gene.
- the promoter and 3′ genomic sequences were derived from the goat beta casein gene.
- the gene was cloned and characterized as described by Roberts et al., 1992, Gene 121:255-262, which is hereby incorporated by reference.
- the expression cassette prior to insertion of immunoglobulin genes, consists of 6.2 kb upstream of the translational start of the beta casein coding sequence and 7.1 kb of genomic sequence downstream of the translational stop of the beta casein gene.
- the TaqI site just upstream of the translational start codon was changed to an XhoI site. This unique XhoI cloning site is at the junction of the upstream and downstream sequences.
- the 3′ beta casein region begins at the PpuMI site found in Exon 7 and continues for 7.1 kb downstream. Included in this sequence are the remaining 18 bp of Exon 7, and all of Exon 8 and Exon 9. These encode the 3′ untranslated regions of the goat beta casein gene, and terminate with the sequence: TAAGGTCCACAGACCGAGACCCACTCACTAGGCAACTGGTCCGTCCAGCTGTTAAGTGA.
- the goat beta casein control sequences were first cloned into the SuperCosl vector (#251301, Stratagene, La Jolla, Calif.) with flanking NotI and SaII sites. This plasmid was then modified by changing the NotI site to a SaII site. This created a 13.3 kb SaIII fragment containing the beta casein expression cassette within the gbc163 vector.
- the genes encoding a human monoclonal antibody directed against a colon cancer cell-surface marker were linked to the casein promoter.
- cDNAs encoding the light and heavy chains of this antibody were cloned from an antibody-secreting hybridoma cell line into a pUC19-derived vector.
- the light and heavy chain cDNAs were present on HindIII/EcoRI fragments of 702 bp and 1416 bp, respectively.
- Light chain gene The pUC19 plasmid containing the light chain cDNA insert was digested with HindIII, blunt-ended by treatment with the Klenow fragment of DNA Polymerase I, and ligated to an oligonucleotide containing an XhoI recognition sequence (#1030, New England Biolabs, Beverly, Mass.).
- Heavy chain gene The pUC19 plasmid containing the heavy chain cDNA was mutagenized using an oligonucleotide with the following sequence: 5′ 5′ AGT GAA TTC ATG CTC GAG AGC CAT GGC CTG GATC 3′.
- the resulting plasmid contains an XhoI site upstream of the heavy chain translation initiation codon.
- the downstream HindIII site was converted to an Xhol site using a synthetic adapter with the sequence 5′ AGC TCC TCG AGG CC 3.′ Digestion of the modified plasmid with XhoI produced the the 1.4 kb modified heavy chain cDNA flanked by XhoI cohesive ends. This fragment was then inserted into the unique XhoI cloning site of gbc163 to yield Bc61 (FIG. 2).
- promoter-linked light and heavy chain genes were isolated from Bc61 and Bc62, respectively, by digestion with SalI. The fragments were then purified by gel electrophoresis followed by CsCl equilibrium gradient centrifugation The DNA was dialyzed extensively against distilled water prior to quantitation.
- Human immunolglobulin can be detected in milk from founder 1-23 and from the progeny of the 1-76 and 1-72 founders. These animals are the second-generation females, 2-76, 2-82, 2-92, and 2-95. The levels of expression range between 0.2 mg/ml to over 1 mg/ml (Table 1).
Abstract
Description
- This invention pertains to a method for the production of monoclonal antibodies in mammal's milk, specifically through the creation of transgenic animals that selectively express foreign antibody genes in mammary epithelial cells.
- Immunoglobulins are heteropolymeric proteins that are normally synthesized, modified, assembled, and secreted from circulating B lymphocytes. Using recombinant DNA technology, it is possible to program cells other than B-lymphocytes to express immunoglobulin genes. The difficulties encountered in this effort stem from several factors: 1) Both heavy and light chains of immunoglobulins must be co-expressed at appropriate levels; 2) Nascent immunoglobulin polypeptides undergo a variety of co- and post-translational modifications that may not occur with sufficient fidelity or efficiency in heterologous cells; 3) Immunoglobulins require accessory chaperone proteins for their assembly; 4) The synthetic and secretory capacity of the cell may be inadequate to secrete large amounts of heterologous proteins; and 5) The secreted immunoglobulins may be unstable in the extracellular milieu of a foreign cell.
- Because immunoglobulins have many therapeutic, diagnostic and industrial applications, there is a need in the art for expression systems in which these proteins can be reproducibly manufactured at a high level, in a functional configuration, and in a form that allows them to be easily harvested and purified The development of transgenic animal technology has raised the possibility of using large animals as genetically programmed protein factories. P.C.T. application WO 90/04036 (published Ap. 19, 1990) discloses the use of transgenic technology for immunoglobulin expression. WO 92/03918 (Mar. 19, 1992) and WO 93/12227 (Jun. 24, 1993) teach the introduction of unrearranged immunoglobulin genes into the germline of transgenic animals. The use of intact immunoglobulin genes (including their respective promoter regions) will result in their expression in lymphocytes and secretion into the bloodstream of the host animal; this necessitates a strategy for suppressing the expression of the host's endogenous immunoglobulins, and raises the problem of purifying the immunoglobulins from serum, which contains many other proteins, including proteolytic enzymes. Furthermore, if the transgenic approach is chosen, heavy and light chain genes must both be incorporated into the host genome, in a manner that enables their comcomittant expression.
- Another option in creating transgenic animals is to link the gene of interest to a heterologous transcriptional promoter that only functions in a defined cell type within the host. In this manner, tissue-specific expression of the transgene may be programmed. U.S. Pat. No. 4,873,316 (issued Oct. 10, 1989) discloses the production of recombinant tissue plasminogen activator (TPA) in the milk of transgenic mice in which the TPA gene is linked to the promoter of the milk protein casein. Other proteins that have been expressed in a similar fashion include cystic fibrosis transmembrane conductance regulator (DiTullio et al.,Bio/Technology 10:74, 1992), urokinase (Meade et al., Bio/Technology 8: 443, 1990), interleukin-2 (Buhler et al., Bio/Technology 8:140, 1990), and antihemophilic factor IX (Clark et al., Bio/Technology 7:487, 1989). Notably, these proteins are all simple single-chain polypeptides that do not require multimerization or assembly prior to secretion.
- It has now been found that when a transgenic mammal is created carrying paired immunoglobulin light and heavy chain genes under the control of the casein promoter, such an animal produces large amounts of assembled immunoglobulins which are secreted in its milk. Using the DNA constructs of the present invention, a surprisingly high efficiency of co-integration of heavy and light chain genes is observed. Using the method and constructs of the present invention, it is possible for the first time to program a mammary epithelial cell to produce and assemble complex tetrameric glycoproteins and secrete them in high quantities.
- Accordingly, it is an object of the, present, invention to provide methods for the large-scale production of immunoglobulins in the milk of transgenic mammals.
- Another object of the invention is to provide methods for the design of synthetic immunoglobulins that can be produced in large quantities in milk.
- Yet another object of the invention is to provide methods for administering therapeutically beneficial antibodies to suckling young, by creating female mammals that excrete such antibodies into their milk.
- A further object of the invention is a transgenic non-human mammal having germ and somatic cells with recombinant DNA sequences encoding immunoglobulin light and heavy chains, where said sequences are operatively linked at their 5′ termini to a mammary specific promoter and at their 3′ end to a sequence comprising a polyadenylation site.
- A further object of the invention is a casein promoter cassette comprising in the 5′ to 3′ direction:
- a) 5′ promoter sequences from the beta casein gene,
- b) an XhoI restriction site, and
- c) 3′ untranslated sequences from the goat beta casein gene.
- These and other objects of the present invention will be apparent to those of ordinary skill in the art in light of the present specification, drawings, and claims.
- FIG. 1 is a schematic representation of the Bc62 plasmid, which contains a 13.9 kb Sal I fragment that comprises cDNA encoding immunoglobulin light chain, flanked on its 5′ and 3′ termini by goat beta casein sequences.
- FIG. 2 is a schematic representation of the Bc61 plasmid, which contains a 14.6 kb Sal I fragment that comprises cDNA encoding immunoglobulin heavy chain, flanked on its 5′ and 3′ termini by goat beta casein sequences.
- FIG. 3 depicts the immunoblot detection of human immunoglobulin heavy chain in the milk, of transgenic mice that were created using the beta casein promoter-linked immunoglobulin genes shown in FIGS. 1 and 2.
- FIG. 4 depicts the immunoblot detection of human immunoglobulin light chain in the milk of transgenic mice that were created using the beta casein promoter-linked immunoglobulin genes shown in FIGS. 1 and 2.
- In one aspect, this invention comprises a method for obtaining heterologous immunoglobulins from the milk of transgenic mammals. Another aspect of the prevent invention comprises the method for creating transgenic mammals by introducing into their germline immunoglobulin cDNA linked to a milk-specific promoter.
- In another aspect, the present invention comprises transgenic mammals having germ cells and somatic cells having recombinant DNA sequences comprising immunoglobulin cDNA linked to a milk-specific promoter.
- In still another aspect, the present invention comprises an isolated DNA comprising an expression cassette having 5′ and 3′ non-coding sequences derived from the goat beta casein gene linked via a unique restriction site that serves as a convenient cloning site for immunoglobulin coding sequences.
- All patent applications, patents and literature cited in this specification are hereby incorporated by reference in their entirety. In the case of inconsistencies, the present disclosure will prevail.
- The present invention pertains to a method for the production of monoclonal antibodies that are excreted into the milk of transgenic animals and the method for production of such animals. This is achieved by engineering DNA construct's in which DNA segments encoding specific paired immunoglobulin heavy and preferentially expressed in mammary epithelial cells. The recombinant DNAs containing the promoter-linked heavy and light chain genes are then coinjected into preimplantation embryos. The a progeny are screened for the presence of both transgenes.
- Representative females from these lines are then milked, and the milk is analyzed for the presence of the monoclonal antibody. In order for the antibody to be present, both heavy and light chain genes must be expressed concurrently in the same cell. The antibodies may be purified from the milk, or the milk itself, comprising the immunoglobulins, may be used to deliver the antibodies to a recipient. This is discussed below.
- The immunoglobulin genes useful in the present invention may be obtained from natural sources e.g. individual B cell clones or hybridomas derived therefrom. Alternately, they may comprise synthetic single-chain antibodies in which the light and heavy variable regions are expressed as part of a single polypeptide. Furthermore, recombinant antibody genes may be used that have been predictively altered by nucleotide substitutions that do or do not change the amino acid sequence, by addition or deletion of sequences, or by creation of hybrid genes in which different regions of the polypeptide are derived from different sources. Antibody genes by their nature are extremely diverse, and thus naturally tolerate a great deal of variation. It will be appreciated by those skilled in the art that the only limitation for producing an antibody by the method of the present invention is that it must assemble into a functional configuration and be secreted in a stable form into the milk.
- The transcriptional promoters useful in practicing the present invention are those promoters that are preferentially activated in mammary epithelial cells, including promoters that control the genes encoding milk proteins such as caseins, beta lactoglobulin (Clark et al., (1989)Bio/Technolog 7: 487-492), whey acid protein (Gordon et al., (1987) Bio/Technology 5: 1183-1187), and lactalbumin (Soulier et al., (1992) FEBS Letts. 297: 13,) Casein promoters may be derived from the alpha, beta, or kappa casein genes of any mammalian species; a preferred promoter is derived from the goat beta casein gene (DiTullio, (1992) Bio/Technology 10:74-77).
- For use in the present invention, a unique XhoI restriction site is introduced at the 3′ terminus of the promoter sequence to allow the routine insertion of immunoglobulin coding sequences. Preferably, the inserted immunoglobulin gene is flanked on its 3′ side by cognate genomic sequences from a mammary-specific gene, to provide a polyadenylation site and transcript-stabilizing sequences. Transcription of the construct in vivo results in the production of a stable mRNA containing casein-derived 5′ untranslated sequences upstream of the translational initiator codon of the immunoglobulin gene and 3′ untranslated sequences downstream of the translational termination codon of the immunoglobulin gene. Finally, the entire cassette (i.e. promoter-immunoglobulin-3′ region) is flanked by restriction sites that enable the promoter-cDNA cassette to be easily excised as a single fragment. This facilitates the removal of unwanted prokaryotic vector-derived DNA sequences prior to injection into fertilized eggs.
- The promoter-linked immunoglobulin heavy and light chain DNAs are then introduced into the germ line of a mammal e.g. cow, sheep, goat, mouse, oxen, camel or pig. Mammals are defined herein as all animals, excluding humans, that have mammary glands and produce milk. Mammalian species that produce milk in large amounts over long periods of time are preferred. Typically, the DNA is injected into the pronuclei of fertilized eggs, which are then implanted into the uterus of a recipient female and allowed to gestate. After birth, the putative transgenic animals are tested for the presence of the introduced DNA This is easily achieved by Southern blot hybridization of DNA extracted from blood cells or other available tissue, using as a probe a segment of the injected gene that shows no cross hybridization with the DNA of the recipient species. Progeny that show evidence of at least one copy of both heavy and light-chain immunoglobulin genes are selected for further analysis.
- Transgenic females may be tested for immunoglobulin secretion into milk, using any of the immunological techniques that are standard in the art (e.g. Western blot, radioimmunoassay, ELISA) The anti-immunoglobulin antibodies used in this analysis may be polyclonal or monoclonal antibodies that detect isolated heavy or light chains or others that react only with fully assembled (H2L2) immunoglobulins.
- The recombinant immunoglobulins are also characterized with respect to their functionality, i.e. binding specificity and affinity for a particular antigen. This is achieved using immunological methods that are standard in the art, such as Scatchard analysis, binding to immobilized antigen., etc. The stability characteristics of an immunoglobulin in the milk of a given species are also assayed, by applying the above-described detection methods to milk that has been incubated for increasing times after recovery from the animal.
- The immunoglobulins produced by the methods of the present invention may be purified from milk, using adsorption to immobilized Protein G, column chromatography, and other methods known to those of ordinary skill in the art of antibody purification.
- The level of production of recombinant immunoglobulins in is an individual transgenic mammal is primarily determined by the site and manner of integration of the transgene after injection into the fertilized egg. Thus, transgenic progeny derived from different injected eggs may vary with respect to this parameter. The amount of recombinant immunoglobulin in milk is therefore monitored in representative progeny, and the highest-producing females are preferred.
- Those skilled in the art will recognize that the methods of the present invention can be used to optimize the production of natural and synthetic immunoglobulins. The steps of creating transgenic animal, testing for the presence of both heavy and the milk of female progeny, and, finally, assessing the quality of the resulting antibodies, can be repeated sequentially, without undue experimentation, to establish preferred constructs for different applications.
- According to the present invention, the nature of the recombinant immunoglobulins and their specific mode of use can vary. In one embodiment, the present invention encompasses high-level expression of antibodies that are harvested and purified from milk and used in purified form. High-level expression is defined herein as the production of about 1 mg/ml of protein. In another embodiment, antibodies are engineered that provide protection to humans against infectious diseases; therapeutic administration is then achieved by drinking the milk. In a still further embodiment, lactating animals are engineered to produce antibodies specifically beneficial to their offspring, which acquire them through suckling. In a still further embodiment, animals produce an antibody that protects the lactating mammal itself against breast pathogens e.g. bacteria that produce mastitis.
- The unexpectedly high-volume expression of immunoglobulins using the method and constructs of the present invention also allows the use of such immunoglobulins in pharmaceutical and chemical settings. By way of non-limiting example the method of the present invention can be used to produce high levels of tetrameric antibodies directed against various pathogens (e.g.E. coli, Salmonella, hepatitis B virus), biologically active peptides (e.g. erythropoietin, tissue plasminogen activator, gamma interferon) and for use in chemical reactions directed against various enzymes. Monoclonal antibodies that bind to the transition state of a chemical reaction can be used in industrial-scale production. Furthermore, monoclonal antibodies are often immobilized on columns for use in the purification of biopharmaceuticals; in such cases, production of the antibodies represents a significant fraction of the cost of purification. The methods of the present invention-facilitate the production of high volume, low cost antibody stocks for use in these types of applications.
- The present invention is further described in the following working examples, which are intended to illustrate the invention without limiting its scope.
- The present invention encompasses a recipient vector into which many different immunoglobulin genes can be interchangeably inserted. The vector contains 5′ milk-specific promoter sequences and 3′ untranslated genomic sequences that flank an XhoI cloning site. This cloning is unique because it is the only one present in the vector. Preferably, the entire expression cassette should be flanked by restriction sites that allow the easy excision of the promoter-linked immunoglobulin gene.
- In this Example, the promoter and 3′ genomic sequences were derived from the goat beta casein gene. The gene was cloned and characterized as described by Roberts et al., 1992, Gene 121:255-262, which is hereby incorporated by reference.
- The expression cassette, prior to insertion of immunoglobulin genes, consists of 6.2 kb upstream of the translational start of the beta casein coding sequence and 7.1 kb of genomic sequence downstream of the translational stop of the beta casein gene. The TaqI site just upstream of the translational start codon was changed to an XhoI site. This unique XhoI cloning site is at the junction of the upstream and downstream sequences.
- It is this XhoI site, included in the sequence CGCGGATCCTCGAGGACC, into which recombinant immunoglobulin genes are inserted. (D. Tullio, (1992)Bio/Technology 10:74-77)
- The 3′ beta casein region begins at the PpuMI site found in Exon 7 and continues for 7.1 kb downstream. Included in this sequence are the remaining 18 bp of Exon 7, and all of Exon 8 and Exon 9. These encode the 3′ untranslated regions of the goat beta casein gene, and terminate with the sequence:
TAAGGTCCACAGACCGAGACCCACTCACTAGGCAACTGGTCCGTCCAGCTGTTAAGTGA. - To engineer restriction sites flanking the casein cassette, the goat beta casein control sequences were first cloned into the SuperCosl vector (#251301, Stratagene, La Jolla, Calif.) with flanking NotI and SaII sites. This plasmid was then modified by changing the NotI site to a SaII site. This created a 13.3 kb SaIII fragment containing the beta casein expression cassette within the gbc163 vector.
- In this Example, the genes encoding a human monoclonal antibody directed against a colon cancer cell-surface marker were linked to the casein promoter. cDNAs encoding the light and heavy chains of this antibody were cloned from an antibody-secreting hybridoma cell line into a pUC19-derived vector. The light and heavy chain cDNAs were present on HindIII/EcoRI fragments of 702 bp and 1416 bp, respectively.
- To adapt the genes for insertion into the casein promoter cassette, XhoI restriction sites were engineered at both ends of each DNA segment as detailed below. In the same step, the region upstream of the immunoglobulin translation initiation codon was modified so that it contained sequences similar to those in the analogous region of the beta casein gene.
- Light chain gene: The pUC19 plasmid containing the light chain cDNA insert was digested with HindIII, blunt-ended by treatment with the Klenow fragment of DNA Polymerase I, and ligated to an oligonucleotide containing an XhoI recognition sequence (#1030, New England Biolabs, Beverly, Mass.).
- The region immediately upstream of the initiating ATG was then mutagenized using an oligonucleotide with the following sequence: 5′ AGT GAA TTC ATG CTC GAG AGC CAT
GGC CTG GATC 3′. Digestion of the final plasmid with XhoI produced the modified light chain cDNA that was flanked by Xhol cohesive ends - The light chain cDNA was then inserted into the unique XhoI cloning site of the gbc163 expression vector described in Example 1, yielding plasmid Bc62 (FIG. 1).
- Heavy chain gene: The pUC19 plasmid containing the heavy chain cDNA was mutagenized using an oligonucleotide with the following sequence: 5′
5′ AGT GAA TTC ATG CTC GAG AGC CAT GGC CTG GATC 3′. - 3.′ The resulting plasmid contains an XhoI site upstream of the heavy chain translation initiation codon.
- The downstream HindIII site was converted to an Xhol site using a synthetic adapter with the
sequence 5′ AGC TCC TCG AGG CC 3.′ Digestion of the modified plasmid with XhoI produced the the 1.4 kb modified heavy chain cDNA flanked by XhoI cohesive ends. This fragment was then inserted into the unique XhoI cloning site of gbc163 to yield Bc61 (FIG. 2). - Prior to injection, promoter-linked light and heavy chain genes were isolated from Bc61 and Bc62, respectively, by digestion with SalI. The fragments were then purified by gel electrophoresis followed by CsCl equilibrium gradient centrifugation The DNA was dialyzed extensively against distilled water prior to quantitation.
- The casein promoter-linked DNA fragments encoding the immunoglobulin heavy and light chains, obtained as described in Example 2, were injected into fertilized mouse eggs using procedures that are standard in the art, as described in Hogan, B., Constantini, F., and Lacey, E.,Manipulating the Mouse Embryo: A Laboratory Manual (Cold Spring Harbor Laboratories, 1986). The resulting progeny were then analyzed for the presence of both antibody gene sequences. DNA was extracted from tail biopsy material and probed using Southern blot analysis. The probes used in the hybridization were the original cDNAs encoding the heavy and light chains. As seen in Table 1, most of the first generation transgenic progeny had incorporated both transgenes.
TABLE 1 Summary of Bc61-Bc62 Mice Founder Sex Bc61 Bc62 Expression 1-2 M Pos. Pos. 1-3 M Pos. Pos. light chain only 1-9 M Pos. Pos. 1-15 F Neg. Pos. Low level lambda chain 1-16 F Pos. Neg. 1-19 F Pos. Pos. N.D 1-23 F Pos. Pos. 1-3 mg/ml 1-24 F Pos. Pos. low level 1-25 M Pos. Neg. 1-39 M Pos. Pos. 1-13 F Pos. Pos. N.D. 1-56 F Pos. Pos. N.D. 1-64 M Pos. Pos. 2-76 F Pos. Pos. 1-3 mg/ml 2-82 F Pos. Pos. 1-3 mg/ml 1-72 M Pos. Pos. 2-92 F Pos. Pos. 0.2-0.5 mg/ml 2-95 F Pos. Pos. 0.2-0.5 mg/ml - Samples of milk from the transgenic mice obtained as described in Example 3 were analyzed for the presence of the heterologous immunoglobulin by Western blot. The heavy chain of the antibody was detected using a horseradish peroxide-linked polyclonal antibody directed against human gamma heavy chain (Antibody #62-8420, Zymed, South San Francisco, Calif.) as shown in FIG. 3. The light chain was detected using antibodies to the human lambda light chain, (Antibody #05-4120, Zymed, South San Francisco, Calif.) shown in FIG. 4. In these Figures, it can be seen that immunoreactive heavy and light chains can be detected in the milk of several animals, but not in the negative control animal CD-1. Human immunolglobulin can be detected in milk from founder 1-23 and from the progeny of the 1-76 and 1-72 founders. These animals are the second-generation females, 2-76, 2-82, 2-92, and 2-95. The levels of expression range between 0.2 mg/ml to over 1 mg/ml (Table 1).
-
1 5 18 base pairs nucleic acid single linear cDNA to mRNA Capra hircus beta casein 5′ 1 CGCGGATCCT CGAGGACC 18 59 base pairs nucleic acid single linear cDNA to mRNA Capra hircus beta casein 3 2 TAAGGTCCAC AGACCGAGAC CCACTCACTA GGCAACTGGT CCGTCCAGCT GTTAAGTGA 59 34 base pairs nucleic acid single linear cDNA to mRNA Capra hircus light chain 5′ 3 AGTGAATTCA TGCTCGAGAG CCATGGCCTG GATC 34 34 base pairs nucleic acid single linear cDNA to mRNA Capra hircus Heavy chain 5′ 4 AGTGAATTCA TGCTCGAGAG CCATGAAGCA CCTG 34 14 base pairs nucleic acid single linear cDNA to mRNA Capra hircus HEAVY CHAIN 3′ 5 AGCTCCTCGA GGCC 14
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/012,904 US20040006776A1 (en) | 1993-12-20 | 1998-01-23 | Transgenic production of antibodies in milk |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/170,579 US5827690A (en) | 1993-12-20 | 1993-12-20 | Transgenic production of antibodies in milk |
US09/012,904 US20040006776A1 (en) | 1993-12-20 | 1998-01-23 | Transgenic production of antibodies in milk |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/170,579 Division US5827690A (en) | 1993-12-20 | 1993-12-20 | Transgenic production of antibodies in milk |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040006776A1 true US20040006776A1 (en) | 2004-01-08 |
Family
ID=22620446
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/170,579 Expired - Lifetime US5827690A (en) | 1993-12-20 | 1993-12-20 | Transgenic production of antibodies in milk |
US08/410,887 Expired - Lifetime US5849992A (en) | 1993-12-20 | 1995-03-27 | Transgenic production of antibodies in milk |
US09/012,904 Abandoned US20040006776A1 (en) | 1993-12-20 | 1998-01-23 | Transgenic production of antibodies in milk |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/170,579 Expired - Lifetime US5827690A (en) | 1993-12-20 | 1993-12-20 | Transgenic production of antibodies in milk |
US08/410,887 Expired - Lifetime US5849992A (en) | 1993-12-20 | 1995-03-27 | Transgenic production of antibodies in milk |
Country Status (12)
Country | Link |
---|---|
US (3) | US5827690A (en) |
EP (2) | EP0741515B1 (en) |
JP (2) | JP3970923B2 (en) |
AT (1) | ATE253817T1 (en) |
AU (2) | AU688845B2 (en) |
CA (1) | CA2178941C (en) |
DE (1) | DE69433325T2 (en) |
DK (1) | DK0741515T3 (en) |
ES (1) | ES2210281T3 (en) |
NZ (1) | NZ278744A (en) |
PT (1) | PT741515E (en) |
WO (1) | WO1995017085A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040172667A1 (en) * | 2002-06-26 | 2004-09-02 | Cooper Richard K. | Administration of transposon-based vectors to reproductive organs |
US20040197910A1 (en) * | 2002-06-26 | 2004-10-07 | Cooper Richard K. | Gene regulation in transgenic animals using a transposon-based vector |
US20040226052A1 (en) * | 2000-10-13 | 2004-11-11 | Meade Harry M. | Methods of producing a target molecule in a transgenic animal and purification of the target molecule |
US20060179500A1 (en) * | 1998-06-19 | 2006-08-10 | Gtc-Biotherapeutics, Inc. | Methods and vectors for improving nucleic acid expression |
US20080118501A1 (en) * | 2005-10-21 | 2008-05-22 | Gtc Biotherapeutics, Inc. | Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use |
US20100081789A1 (en) * | 2008-09-25 | 2010-04-01 | Cooper Richard K | Novel Vectors for Production of Interferon |
US20100093036A1 (en) * | 2008-09-25 | 2010-04-15 | Cooper Richard K | Novel Vectors for Production of Growth Hormone |
US20100099148A1 (en) * | 2008-09-25 | 2010-04-22 | Cooper Richard K | Novel Vectors for Production of Antibodies |
US20100199366A1 (en) * | 2003-12-24 | 2010-08-05 | Richard Cooper | Gene therapy using transposon-based vectors |
US20100261227A1 (en) * | 2009-04-09 | 2010-10-14 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Production of Proteins Using Transposon-Based Vectors |
US20110104049A1 (en) * | 2005-02-15 | 2011-05-05 | Gtc Biotherapeutics, Inc. | Method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
US7939317B1 (en) | 1986-04-09 | 2011-05-10 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
US20110229460A1 (en) * | 2008-05-01 | 2011-09-22 | Gtc Biotherapeutics, Inc. | anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
US20170163823A1 (en) * | 2009-01-28 | 2017-06-08 | Sharp Kabushiki Kaisha | Image forming apparatus, image printing method, external device, recording medium and communication system |
US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
US10174110B2 (en) | 2013-02-13 | 2019-01-08 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-TNF-α antibodies and uses thereof |
US10611826B2 (en) | 2013-07-05 | 2020-04-07 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Affinity chromatography matrix |
US11553712B2 (en) | 2010-12-30 | 2023-01-17 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Glycols as pathogen inactivating agents |
Families Citing this family (529)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
GB9406974D0 (en) | 1994-04-08 | 1994-06-01 | Pharmaceutical Proteins Ltd | Transgenic production |
WO1998037224A1 (en) * | 1997-02-25 | 1998-08-27 | Genzyme Transgenics Corporation | Transgenically produced non-secreted proteins |
US6011197A (en) | 1997-03-06 | 2000-01-04 | Infigen, Inc. | Method of cloning bovines using reprogrammed non-embryonic bovine cells |
JP2001520041A (en) | 1997-10-20 | 2001-10-30 | ジェンザイム トランスジェニックス コーポレイション | Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cellular systems |
EP0921189B1 (en) * | 1997-11-14 | 2005-01-12 | Sankyo Company Limited | Transgenic animal allergy models and methods for their use |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
HUP0102530A3 (en) * | 1998-09-11 | 2006-02-28 | Korea Advanced Inst Sci & Tech | Mammary gland tissue-specific expression system using betha-casein promoter site of korean native goat |
US6258998B1 (en) | 1998-11-24 | 2001-07-10 | Infigen, Inc. | Method of cloning porcine animals |
US6700037B2 (en) | 1998-11-24 | 2004-03-02 | Infigen, Inc. | Method of cloning porcine animals |
CN1328571B (en) | 1998-12-23 | 2016-08-31 | 辉瑞大药厂 | The human monoclonal antibodies of anti-CTLA-4 |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
US6682736B1 (en) * | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
US7208576B2 (en) * | 1999-01-06 | 2007-04-24 | Merrimack Pharmaceuticals, Inc. | Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof |
DE60037397T2 (en) | 1999-01-06 | 2008-06-05 | Merrimack Pharmaceuticals, Inc., Cambridge | EXPRESSION OF DERIVED, HUMAN ALPHA-FETOPROTEIN IN TRANSGENIC ANIMALS |
SI2314315T1 (en) | 1999-06-01 | 2015-04-30 | Biogen Idec Ma Inc. | A blocking monoclonal antibody to the human alpha1 I-domain of VLA-1, and its use for the treatment of inflammatory disorders |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
EP1194570A1 (en) * | 1999-06-23 | 2002-04-10 | PPL Therapeutics (Scotland) Limited | Fusion proteins incorporating lysozyme |
WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US20030129745A1 (en) * | 1999-10-28 | 2003-07-10 | Robl James M. | Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
US7414170B2 (en) * | 1999-11-19 | 2008-08-19 | Kirin Beer Kabushiki Kaisha | Transgenic bovines capable of human antibody production |
US7820878B2 (en) * | 1999-11-19 | 2010-10-26 | Kyowa Hakko Kirin Co., Ltd. | Production of ungulates, preferably bovines that produce human immunoglobulins |
WO2001035735A1 (en) * | 1999-11-19 | 2001-05-25 | Hematech, Llc | Production of ungulates, preferably bovines that produce human immunoglobulins |
US7074983B2 (en) * | 1999-11-19 | 2006-07-11 | Kirin Beer Kabushiki Kaisha | Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin |
WO2001098520A1 (en) * | 2000-06-19 | 2001-12-27 | Genzyme Transgenics Corp. | Transgenically produced platelet derived growth factor |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
UA81743C2 (en) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
KR100882030B1 (en) | 2000-11-17 | 2009-02-09 | 교와 핫꼬 기린 가부시키가이샤 | Expression of Xenogenous (Human) Immunoglobulins in Cloned, Transgenic Ungulates |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
PE20020574A1 (en) | 2000-12-06 | 2002-07-02 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA |
US7491534B2 (en) | 2000-12-22 | 2009-02-17 | Kirin Holdings Kabushiki Kaisha | Methods for altering cell fate to generate T-cells specific for an antigen of interest |
MXPA03005624A (en) | 2000-12-22 | 2004-12-03 | Vaurox Llc | Methods for cloning mammals using reprogrammed donor chromatin or donor cells. |
US20020142397A1 (en) * | 2000-12-22 | 2002-10-03 | Philippe Collas | Methods for altering cell fate |
AU2002231736A1 (en) | 2000-12-22 | 2002-07-08 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Use of repulsive guidance molecule (rgm) and its modulators |
PE20020801A1 (en) * | 2001-01-05 | 2002-09-06 | Pfizer | ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR RECEPTOR |
AU2002258778C1 (en) * | 2001-04-13 | 2008-12-04 | Biogen Ma Inc. | Antibodies to VLA-1 |
US20050107596A1 (en) * | 2001-04-23 | 2005-05-19 | Madaio Michael P. | Anti-alpha3(IV)nc1 monoclonal antibodies and animal model for human anti-glomerular basement membrane autoantibody disease |
GB0110029D0 (en) * | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
WO2002092017A2 (en) * | 2001-05-16 | 2002-11-21 | Albert Einstein College Of Medicine Of Yeshiva University | Human antipneumococcal antibodies from non-human animals |
DK2279753T3 (en) | 2001-10-10 | 2015-11-23 | Novo Nordisk As | The conversion of peptides and glycokonjugering |
PT2279755E (en) | 2001-10-10 | 2014-06-04 | Ratiopharm Gmbh | Remodelling and glycoconjugation of fibroblast growth factor (fgf) |
US7151164B2 (en) * | 2002-02-14 | 2006-12-19 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
AR039067A1 (en) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
ES2624547T3 (en) | 2001-11-14 | 2017-07-14 | Janssen Biotech, Inc. | Anti il 6 antibodies, compositions, methods and uses |
US7230085B2 (en) * | 2001-11-28 | 2007-06-12 | Immunomedics, Inc. | Anti-DOTA antibody |
AR037456A1 (en) | 2001-11-30 | 2004-11-10 | Biogen Inc | ANTIBODIES AGAINST MONOCITARY CHEMOTHOTAL PROTEINS |
US6578724B1 (en) * | 2001-12-29 | 2003-06-17 | United States Can Company | Connector for use in packaging aerosol containers |
WO2003062278A1 (en) | 2002-01-25 | 2003-07-31 | G2 Therapies Ltd | MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR |
US8287864B2 (en) * | 2002-02-14 | 2012-10-16 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
AR038568A1 (en) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | ANTI-A BETA ANTIBODIES AND ITS USE |
SI2336184T1 (en) | 2002-02-25 | 2015-04-30 | Biogen Idec Ma Inc. | Administration of agents for the treatment of inflammation |
JP2005518802A (en) * | 2002-02-28 | 2005-06-30 | イーライ・リリー・アンド・カンパニー | Anti-interleukin-1 beta analog |
EP2865688A1 (en) | 2002-03-01 | 2015-04-29 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
AU2003261071C1 (en) | 2002-03-13 | 2008-12-11 | Biogen Idec Ma Inc. | Anti-AlphavBeta6 antibodies |
ES2384168T3 (en) * | 2002-04-12 | 2012-07-02 | Medarex, Inc. | Treatment procedures using CTLA-4 antibodies |
NZ536341A (en) | 2002-05-17 | 2008-05-30 | Kirin Holdings Kk | Transgenic ungulates capable of human antibody production |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
ATE528014T1 (en) | 2002-06-07 | 2011-10-15 | Dyax Corp | POLYPEPTIDE WITH MODIFIED KUNITZ DOMAINS |
CA2490409A1 (en) | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
ES2442615T5 (en) | 2002-07-18 | 2023-03-16 | Merus Nv | Recombinant production of antibody mixtures |
AU2003248982B2 (en) | 2002-08-01 | 2009-12-10 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
US7166576B2 (en) * | 2002-08-28 | 2007-01-23 | Dyax Corp. | Methods for preserving organs and tissues |
JP2006508062A (en) * | 2002-09-17 | 2006-03-09 | ジーティーシー バイオセラピューティックス インコーポレイテッド | Isolation of immunoglobulin molecules lacking inter-heavy chain disulfide bonds. |
US7541440B2 (en) | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
KR20050093761A (en) * | 2002-11-08 | 2005-09-23 | 헤마테크, 엘엘씨 | Transgenic ungulates having reduced prion protein activity and uses thereof |
US20040101939A1 (en) * | 2002-11-22 | 2004-05-27 | Santora Ling C. | Method for reducing or preventing modification of a polypeptide in solution |
US20040162414A1 (en) * | 2002-11-22 | 2004-08-19 | Santora Ling C. | Method for reducing or preventing modification of a polypeptide in solution |
EP1565564A4 (en) * | 2002-11-27 | 2006-06-07 | Gtc Biotherapeutics Inc | Modified antibodies stably produced in milk and methods of producing same |
US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
KR101260497B1 (en) | 2003-01-24 | 2013-09-12 | 엘란 파마슈티칼스, 인크. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
EP1615945B1 (en) | 2003-04-09 | 2011-09-28 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
AU2004255557B2 (en) | 2003-06-09 | 2010-06-10 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
JP4667383B2 (en) | 2003-06-13 | 2011-04-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Aglycosyl anti-CD154 (CD40 ligand) antibody and use thereof |
EP1660519B1 (en) * | 2003-07-29 | 2014-05-14 | Immunomedics, Inc. | Conjugates comprising 2-[18F]fluoro-2-deoxy-D-glucose and a peptide molecule |
EP2216342B1 (en) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
HN2004000285A (en) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTIBODIES DIRECTED TO c-MET |
AU2004263896A1 (en) | 2003-08-08 | 2005-02-17 | Genenews Inc. | Osteoarthritis biomarkers and uses thereof |
US20050079184A1 (en) * | 2003-08-08 | 2005-04-14 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
EP1670931A2 (en) * | 2003-09-05 | 2006-06-21 | GTC Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
AR045563A1 (en) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
WO2005033281A2 (en) | 2003-09-30 | 2005-04-14 | Sterrenbeld Biotechnologie North America, Inc. | A process of making transgenic mammals that produce exogenous proteins in milk and transgenic mammals produced thereby |
UA89481C2 (en) | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Human epo mimetic hinge core mimetibodies, compositions, methods and uses |
CN1956738B (en) | 2004-01-09 | 2013-05-29 | 辉瑞大药厂 | Antibodies to MAdCAM |
CA2554054C (en) | 2004-01-20 | 2013-06-04 | Merus B.V. | Mixtures of binding proteins |
US20050186608A1 (en) * | 2004-02-19 | 2005-08-25 | Olsen Byron V. | Method for the production of transgenic proteins useful in the treatment of obesity and diabetes |
US20050197496A1 (en) * | 2004-03-04 | 2005-09-08 | Gtc Biotherapeutics, Inc. | Methods of protein fractionation using high performance tangential flow filtration |
EA011583B1 (en) * | 2004-03-31 | 2009-04-28 | Сентокор, Инк. | Human glp-1 mimetibodies, compositions, methods and uses |
WO2005104835A2 (en) * | 2004-04-22 | 2005-11-10 | Kirin Beer Kabushiki Kaisha | Transgenic animals and uses thereof |
DK2287195T3 (en) | 2004-07-01 | 2019-08-19 | Innate Pharma | PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND USE IN DIAGNOSTICS AND THERAPY |
CN101014365B (en) * | 2004-07-16 | 2011-04-13 | 辉瑞产品公司 | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
CA2575838A1 (en) | 2004-07-26 | 2006-03-30 | Biogen Idec Ma Inc. | Anti-cd154 antibodies |
MX2007001679A (en) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevention and treatment of synucleinopathic and amyloidogenic disease. |
CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
US7393662B2 (en) * | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
DE602005026219D1 (en) * | 2004-10-01 | 2011-03-17 | Max Planck Gesellschaft | AGAINST THE MAMMALIAN EAG1 ION CHANNEL PROPER ANTIBODIES |
ZA200703561B (en) | 2004-10-05 | 2009-09-30 | Wyeth Corp | Methods and compositions for improving recombinant protein production |
KR20070084170A (en) * | 2004-10-13 | 2007-08-24 | 아블린쓰 엔.브이. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease |
EP1827491A4 (en) | 2004-11-19 | 2010-07-14 | Biogen Idec Inc | Treatment for multiple sclerosis |
US20090169477A1 (en) * | 2004-12-03 | 2009-07-02 | Michael Panzara | Delaying or preventing onset of multiple sclerosis |
US20060121004A1 (en) * | 2004-12-07 | 2006-06-08 | Yann Echelard | Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin |
US20060130159A1 (en) * | 2004-12-09 | 2006-06-15 | Nick Masiello | Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum |
AR052051A1 (en) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | AB HUMANIZED ANTIBODIES USED TO IMPROVE COGNITION |
US7713695B2 (en) | 2005-02-07 | 2010-05-11 | Genenews, Inc. | Mild osteoarthritis biomarkers and uses thereof |
DK2529619T3 (en) | 2005-02-17 | 2016-01-11 | Biogen Ma Inc | Treatment of neurological disorders |
JP2008531719A (en) | 2005-03-02 | 2008-08-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | KIM-1 antibody for the treatment of Th2-mediated conditions |
ES2665422T3 (en) | 2005-03-03 | 2018-04-25 | Immunomedics Inc. | Humanized L243 antibodies |
DK2620450T3 (en) | 2005-03-08 | 2019-02-04 | Pfizer Prod Inc | Antibody Compositions against CTLA-4 |
EP2567976B1 (en) | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
EP3058955B1 (en) | 2005-03-24 | 2019-05-29 | Millennium Pharmaceuticals, Inc. | Antibodies that bind ov064 and methods of use therefor |
PT2343320T (en) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anti-gitr antibodies and uses thereof |
PL1863519T3 (en) | 2005-03-31 | 2014-03-31 | Massachusetts Gen Hospital | Modulating hgf/hgfr activity for treating lymphodema |
JP2008537595A (en) | 2005-04-04 | 2008-09-18 | バイオジェン アイデック エムエイ インコーポレイテッド | Methods and products for assessing immune responses to therapeutic proteins |
US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
DOP2006000093A (en) * | 2005-04-25 | 2007-01-31 | Pfizer | ANTIBODIES AGAINST MYOSTATIN |
KR100990027B1 (en) | 2005-04-26 | 2010-10-26 | 화이자 인코포레이티드 | P-cadherin antibodies |
JO3058B1 (en) | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | Anti-IL-6 Antibodies,Compositions,Methods and uses |
EA026785B1 (en) | 2005-05-10 | 2017-05-31 | Инсайт Холдингс Корпорейшн | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
KR20080023317A (en) | 2005-05-27 | 2008-03-13 | 바이오겐 아이덱 엠에이 인코포레이티드 | Tweak binding antibodies |
EP2937360A1 (en) | 2005-06-17 | 2015-10-28 | Merck Sharp & Dohme Corp. | Ilt3 binding molecules and uses therefor |
JP2009501006A (en) | 2005-06-30 | 2009-01-15 | セントカー・インコーポレーテツド | Anti-IL-23 antibodies, compositions, methods and uses |
CN102875681A (en) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | Anti-alpha v beta 6 antibodies and uses thereof |
EP1945257A4 (en) * | 2005-08-08 | 2009-05-06 | Onconon Llc | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
RS54393B1 (en) * | 2005-09-07 | 2016-04-28 | Amgen Fremont Inc. | Human monoclonal antibodies to activin receptor-like kinase-1 |
ES2542501T3 (en) | 2005-09-30 | 2015-08-06 | Abbvie Deutschland Gmbh & Co Kg | Protein binding domains of the protein family of repulsive targeting molecules (RGM) and functional fragments thereof, as well as their use |
AU2012201010B2 (en) * | 2005-10-21 | 2015-01-22 | Genzyme Corporation | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
EP1945816B1 (en) | 2005-10-21 | 2011-07-27 | GeneNews Inc. | Method and apparatus for correlating levels of biomarker products with disease |
WO2007067959A2 (en) | 2005-12-07 | 2007-06-14 | Medarex, Inc. | Ctla-4 antibody dosage escalation regimens |
WO2007068255A1 (en) | 2005-12-15 | 2007-06-21 | Genmab A/S | Use of effector-function-deficient antibodies for treatment of auto-immune diseases |
SI3219328T1 (en) | 2005-12-29 | 2020-10-30 | Janssen Biotech, Inc. | Human anti-il-23 antibodies, compositions, method and uses |
DE602007008365D1 (en) | 2006-01-18 | 2010-09-23 | Gen Hospital Corp | METHOD FOR INCREASING THE LYMPHATIC FUNCTION |
US7531632B2 (en) * | 2006-02-16 | 2009-05-12 | Gtc Biotherapeutics, Inc. | Clarification of transgenic milk using depth filtration |
CA2644148A1 (en) | 2006-03-03 | 2007-09-13 | University Of Southern California | Angiogenesis pathway gene polymorphisms for therapy selection |
WO2007115148A2 (en) * | 2006-03-31 | 2007-10-11 | Centocor, Inc. | Human mimetic epo hinge core mimetibodies |
MX2008012754A (en) * | 2006-04-07 | 2009-04-27 | Us Gov Health & Human Serv | Antibody compositions and methods for treatment of neoplastic disease. |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
AU2007320075A1 (en) * | 2006-05-19 | 2008-05-22 | Amgen Inc. | Antibodies to SARS coronavirus |
DK2034830T3 (en) | 2006-05-25 | 2014-10-27 | Biogen Idec Inc | ANTI-VLA-1 ANTIBODY FOR TREATMENT OF CASES |
FR2901707B1 (en) | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, EACH FACTOR VII MOLECULE HAVING TWO N-GLYCOSYLATION SITES WITH DEFINED GLYCANNIC PATTERNS |
CA2655903A1 (en) * | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
JP2009542810A (en) | 2006-07-10 | 2009-12-03 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Compositions and methods for inhibiting the growth of SMAD4-deficient cancers |
FR2904558B1 (en) * | 2006-08-01 | 2008-10-17 | Lab Francais Du Fractionnement | "RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, MAJORITYALLY HAVING BIANTENNAE, BISIALYLATED AND NON-FUCOSYLATED GLYCANNIC FORMS" |
MX2009001291A (en) | 2006-08-04 | 2009-03-10 | Astrazeneca Ab | Human antibodies to erbb 2. |
CN101506237B (en) * | 2006-08-22 | 2014-05-07 | G2炎症私人有限公司 | Anti-c5ar antibodies with improved properties |
JP5476122B2 (en) | 2006-09-26 | 2014-04-23 | ゲンマブ エー/エス | Combination treatment of CD38 expressing tumor |
MX2009003542A (en) * | 2006-10-12 | 2009-04-15 | Wyeth Corp | Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates. |
CA2668295A1 (en) | 2006-11-03 | 2008-05-08 | U3 Pharma Gmbh | Fgfr4 antibodies |
UY30820A1 (en) * | 2006-12-21 | 2008-07-03 | Centocor Inc | USE OF LONG-TERM ACTION GLP-1 RECEPTOR AGONISTS TO IMPROVE INSULIN SENSITIVITY AND LIPID PROFILES |
WO2008083169A2 (en) * | 2006-12-26 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
CA2673752A1 (en) * | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for stimulating an immune response |
US7989173B2 (en) * | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
FR2910786B1 (en) * | 2006-12-29 | 2017-08-11 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) | "PROCESS FOR EXTRACTING A PROTEIN PRESENT IN MILK" |
EP2126117A2 (en) * | 2007-01-18 | 2009-12-02 | University Of Southern California | Gene polymorphisms predictive for dual tki therapy |
ES2570182T3 (en) | 2007-02-23 | 2016-05-17 | Prothena Biosciences Ltd | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP2583978B1 (en) | 2007-02-23 | 2016-04-06 | Prothena Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
CN103214577B (en) | 2007-03-22 | 2015-09-02 | 生物基因Ma公司 | Specific binding CD154 comprises associated proteins of antibody, antibody derivatives and antibody fragment and uses thereof |
AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
FR2915398B1 (en) * | 2007-04-25 | 2012-12-28 | Lab Francais Du Fractionnement | "SET OF MEANS FOR THE TREATMENT OF MALIGNANT PATHOLOGY, AUTOIMMUNE DISEASE OR INFECTIOUS DISEASE" |
AU2008255352B2 (en) | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
AR067011A1 (en) | 2007-06-14 | 2009-09-30 | Biogen Idec Inc | FORMULATIONS OF ANTIBODIES |
WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
WO2009020748A2 (en) * | 2007-07-16 | 2009-02-12 | Avaxia Biologics, Inc. | Antibody therapy for modulating function of intestinal receptors |
SI2915564T1 (en) | 2007-09-28 | 2021-03-31 | Alexion Pharmaceuticals, Inc. | Antidotes for factor XA inhibitors and methods of using the same |
EP2244735A4 (en) | 2007-10-02 | 2011-02-23 | Avaxia Biologics Inc | Antibody therapy for use in the digestive tract |
JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
US8663980B2 (en) * | 2007-10-26 | 2014-03-04 | Janssen Biotech, Inc. | Vectors, host cells, and methods of production and uses |
NZ585465A (en) | 2007-11-12 | 2012-12-21 | Monoclonal antibodies which bind to the extracellular domain of the axl receptor tyrosine kinase | |
US20090169549A1 (en) * | 2007-12-19 | 2009-07-02 | The Board Of Regents Of The University Of Texas System | Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use |
US9605035B2 (en) | 2008-01-10 | 2017-03-28 | Research Development Foundation | Vaccines and diagnostics for the ehrlichioses |
MX2010009190A (en) * | 2008-02-20 | 2010-09-10 | G2 Inflammation Pty Ltd | HUMANIZED ANTI-C5aR ANTIBODIES. |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
SG196839A1 (en) | 2008-04-25 | 2014-02-13 | Dyax Corp | Antibodies against fcrn and use thereof |
ES2620285T3 (en) | 2008-05-02 | 2017-06-28 | Novartis Ag | Binding molecules based on improved fibronectin and their uses |
ES2797126T3 (en) | 2008-05-30 | 2020-12-01 | Xbiotech Inc | IL-1 alpha antibody uses |
CN102076716A (en) | 2008-06-25 | 2011-05-25 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | Stable and soluble antibodies inhibiting tnfa |
JP5856480B2 (en) | 2008-06-25 | 2016-02-09 | エスバテック − ア ノバルティスカンパニー エルエルシー | Humanization of rabbit antibodies using a versatile antibody framework |
CN104042611B (en) | 2008-07-08 | 2019-05-14 | 因塞特控股公司 | 1 of inhibitor as indoleamine 2,3-dioxygenase, 2,5- oxadiazoles |
BRPI0917204A2 (en) * | 2008-07-21 | 2015-12-01 | Immunomedics Inc | structural antibody variants for better therapeutic characteristics |
WO2010019656A1 (en) * | 2008-08-12 | 2010-02-18 | Wyeth | Humanized anti-rage antibody |
EA026110B1 (en) | 2008-08-14 | 2017-03-31 | Сефалон Острэйлиа Пти Лтд. | Anti-il-12/il-23 antibodies |
EP2349329A4 (en) | 2008-10-14 | 2012-10-31 | Dyax Corp | Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
UA109633C2 (en) | 2008-12-09 | 2015-09-25 | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
EP2376117A1 (en) | 2008-12-17 | 2011-10-19 | Genentech, Inc. | Hepatitis c virus combination therapy |
PT2414517T (en) | 2009-03-30 | 2016-12-27 | Portola Pharm Inc | Antidotes for factor xa inhibitors and methods of using the same |
CA2758548A1 (en) * | 2009-04-17 | 2010-10-21 | Biogen Idec Ma Inc. | Compositions and methods to treat acute myelogenous leukemia |
EP2270053A1 (en) | 2009-05-11 | 2011-01-05 | U3 Pharma GmbH | Humanized AXL antibodies |
US20100304873A1 (en) * | 2009-05-28 | 2010-12-02 | Lipa Markowitz | Bowling Ball and Football Game Controller |
US8399624B1 (en) | 2009-06-25 | 2013-03-19 | Esbatech, An Alcon Biomedical Research Unit Llc | Acceptor framework for CDR grafting |
ES2605801T3 (en) | 2009-07-15 | 2017-03-16 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor Xa inhibitors for use in the prevention of bleeding |
AU2010286361A1 (en) | 2009-08-31 | 2012-03-15 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
IN2012DN01663A (en) | 2009-09-16 | 2015-06-05 | Immunomedics Inc | |
EP3349010A1 (en) | 2009-10-11 | 2018-07-18 | Biogen MA Inc. | Anti-vla-4 related assays |
MX2012003198A (en) | 2009-10-23 | 2012-06-12 | Millennium Pharm Inc | Anti-gcc antibody molecules and related compositions and methods. |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
ES2562832T3 (en) | 2009-12-08 | 2016-03-08 | Abbvie Deutschland Gmbh & Co Kg | Monoclonal antibodies against the RGM protein for use in the treatment of degeneration of the retinal nerve fiber layer |
DK3459564T3 (en) | 2010-01-06 | 2022-02-07 | Takeda Pharmaceuticals Co | PLASMA CALLIC REINBANDING PROTEINS |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
ME02646B (en) | 2010-02-08 | 2017-06-20 | Regeneron Pharma | Common light chain mouse |
AU2011215900A1 (en) | 2010-02-10 | 2012-07-26 | Immunogen, Inc. | CD20 antibodies and uses thereof |
LT2558499T (en) | 2010-04-16 | 2017-07-25 | Biogen Ma Inc. | Anti-vla-4 antibodies |
EP2384766A1 (en) * | 2010-05-03 | 2011-11-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel antibody to a carbonic anhydrase |
DK2580243T3 (en) | 2010-06-09 | 2020-01-13 | Genmab As | ANTIBODIES AGAINST HUMAN CD38 |
ME02919B (en) | 2010-06-15 | 2018-04-20 | Genmab As | Human antibody drug conjugates against tissue factor |
CA2801210C (en) | 2010-06-19 | 2020-07-21 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
PT2591006T (en) | 2010-07-09 | 2019-07-29 | Bioverativ Therapeutics Inc | Processable single chain molecules and polypeptides made using same |
JP2013536175A (en) | 2010-07-16 | 2013-09-19 | アブリンクス エン.ヴェー. | Modified single domain antigen binding molecules and uses thereof |
FR2962908A1 (en) | 2010-07-20 | 2012-01-27 | Lfb Biotechnologies | ANTI-CD20 ANTIBODY FORMULATION |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
CA2805361A1 (en) | 2010-09-29 | 2012-04-05 | Universite De Liege | Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis |
UY33679A (en) | 2010-10-22 | 2012-03-30 | Esbatech | STABLE AND SOLUBLE ANTIBODIES |
KR101919170B1 (en) | 2010-11-19 | 2018-11-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Neutralizing anti-ccl20 antibodies |
EP3153583B1 (en) | 2010-12-31 | 2021-10-20 | BioAtla, Inc. | Express humanization of antibodies |
IL310186A (en) | 2011-01-06 | 2024-03-01 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins |
SA112330278B1 (en) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | Novel modulators and methods of use |
WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
JP6130350B2 (en) | 2011-03-30 | 2017-05-17 | アブリンクス エン.ヴェー. | Methods of treating immune disorders with single domain antibodies against TNFα |
US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
WO2012140627A1 (en) | 2011-04-15 | 2012-10-18 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
KR102014554B1 (en) | 2011-06-02 | 2019-08-26 | 다이액스 코포레이션 | Fc receptor binding proteins |
CN103596982B (en) | 2011-06-06 | 2016-11-02 | 诺沃—诺迪斯克有限公司 | Therapeutic antibodies |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
EP3865581A1 (en) | 2011-08-05 | 2021-08-18 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
BR112014003110A2 (en) * | 2011-08-10 | 2018-10-09 | Lab Francais Du Fractionnement | composition, method for producing a highly galactosylated population of antibodies, mammary gland epithelial cells and tramsgenic non-human mammal |
JP6317670B2 (en) | 2011-08-15 | 2018-04-25 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | Compositions and methods related to antibodies to staphylococcal protein A |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
ES2942483T3 (en) | 2011-10-05 | 2023-06-01 | Oned Mat Inc | Silicon Nanostructure Active Materials for Lithium Ion Batteries and Related Processes, Compositions, Components and Devices |
HUE026344T2 (en) | 2011-10-11 | 2016-05-30 | Univ D'aix-Marseille | An anti-HIV-1 Tat monoclonal antibody |
RU2014114015A (en) | 2011-11-08 | 2015-12-20 | Пфайзер Инк. | METHODS FOR TREATING INFLAMMATORY DISORDERS USING ANTIBODIES AGAINST M-CSF |
RU2014124530A (en) | 2011-11-23 | 2015-12-27 | Идженика, Инк. | ANTIBODIES TO CD98 AND WAYS OF THEIR APPLICATION |
EP3800200A1 (en) | 2011-12-14 | 2021-04-07 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
US9636398B2 (en) | 2011-12-14 | 2017-05-02 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
CA2860579A1 (en) | 2012-01-10 | 2013-07-18 | Biogen Idec Ma Inc. | Enhancement of transport of therapeutic molecules across the blood brain barrier |
LT2807192T (en) | 2012-01-27 | 2018-07-25 | AbbVie Deutschland GmbH & Co. KG | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
ES2732243T3 (en) | 2012-02-16 | 2019-11-21 | Santarus Inc | Pharmaceutical compositions of ANTI-VLA1 antibodies (CD49A) |
PT2817338T (en) | 2012-02-24 | 2017-11-13 | Abbvie Stemcentrx Llc | Dll3 modulators and methods of use |
KR102143887B1 (en) | 2012-03-16 | 2020-08-12 | 유니버시티 헬스 네트워크 | Methods and compositions for modulating toso activity |
SI2828284T1 (en) | 2012-03-20 | 2019-10-30 | Biogen Ma Inc | Jcv neutralizing antibodies |
SG10201913376XA (en) | 2012-04-20 | 2020-02-27 | Merus Nv | Methods and means for the production of ig-like molecules |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
CN104703622B (en) | 2012-04-26 | 2017-05-24 | 芝加哥大学 | Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease |
US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
WO2013169377A1 (en) | 2012-05-10 | 2013-11-14 | Massachusetts Institute Of Technology | Agents for influenza neutralization |
KR101937733B1 (en) | 2012-05-24 | 2019-01-11 | 마운트게이트 그룹 리미티드 | Compositions and methods related to prevention and treatment of rabies infection |
US10202595B2 (en) | 2012-06-08 | 2019-02-12 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
CA2879763C (en) | 2012-08-03 | 2020-12-01 | Simon LOWRY | The use of antithrombin in extracorporeal membrane oxygenation |
US9499607B2 (en) | 2012-08-07 | 2016-11-22 | Massachusetts Institute Of Technology | Anti-dengue virus antibodies and uses thereof |
UA118441C2 (en) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Antibodies recognizing alpha-synuclein |
CA2887129A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
EA034757B1 (en) | 2012-12-10 | 2020-03-17 | Байоджен Ма Инк. | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
TWI635098B (en) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | Antibodies comprising chimeric constant domains |
CA2894918A1 (en) | 2013-02-15 | 2014-08-21 | Esbatech - A Novartis Company Llc | Acceptor framework for cdr grafting |
RS64664B1 (en) | 2013-02-15 | 2023-11-30 | Bioverativ Therapeutics Inc | Optimized factor viii gene |
JP2016506752A (en) | 2013-02-20 | 2016-03-07 | エスバテック − ア ノバルティスカンパニー エルエルシー | Acceptor framework for CDR grafting |
US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
WO2014144666A2 (en) | 2013-03-15 | 2014-09-18 | The University Of Chicago | Methods and compositions related to t-cell activity |
TWI745671B (en) | 2013-03-15 | 2021-11-11 | 美商百歐維拉提夫治療公司 | Factor ix polypeptide formulations |
CN105705165B (en) | 2013-03-15 | 2020-04-24 | 纪念斯隆-凯特琳癌症中心 | High affinity anti-GD 2 antibodies |
EA201591806A1 (en) | 2013-03-15 | 2016-01-29 | Байоджен Ма Инк. | TREATMENT AND PREVENTION OF ACUTE RENAL FAILURE WITH THE USE OF ANTI-ALPHA-V-BETA-5 ANTIBODIES |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
WO2014143739A2 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
US10526375B2 (en) | 2013-06-05 | 2020-01-07 | Massachusetts Institute Of Technology | Human Adaptation of H7 HA |
EP3632467B1 (en) | 2013-06-07 | 2023-09-27 | Duke University | Inhibitors of complement factor h |
US20160296609A1 (en) | 2013-06-28 | 2016-10-13 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
US9803017B2 (en) | 2013-07-05 | 2017-10-31 | University Of Washington Through Its Center For Commercialization | Soluble MIC neutralizing monoclonal antibody for treating cancer |
US9850302B2 (en) | 2013-07-12 | 2017-12-26 | Prothena Biosciences Limited | Antibodies that recognize IAPP |
WO2015004633A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize islet-amyloid polypeptide (iapp) |
US9993566B2 (en) | 2013-08-28 | 2018-06-12 | Abbvie Stemcentrx Llc | SEZ6 modulators and methods of use |
WO2015057939A1 (en) | 2013-10-18 | 2015-04-23 | Biogen Idec Ma Inc. | Anti-s1p4 antibodies and uses thereof |
KR20230010003A (en) | 2013-10-21 | 2023-01-17 | 다케다 파머수티컬 컴패니 리미티드 | Diagnosis and treatment of autoimmune diseases |
ES2920677T3 (en) | 2013-12-24 | 2022-08-08 | Janssen Pharmaceutica Nv | Anti-VISTA Antibodies and Fragments |
CN106103483A (en) | 2014-01-13 | 2016-11-09 | 贝勒研究院 | The novel vaccine of the related disease of anti-HPV with HPV |
MX2016009428A (en) | 2014-01-21 | 2017-04-13 | Dyax Corp | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema. |
JP6837840B2 (en) | 2014-01-24 | 2021-03-10 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | Binding protein and how to use it |
SG11201606322XA (en) | 2014-02-07 | 2016-08-30 | Medimmune Llc | Novel assay to detect human periostin |
MX2016009991A (en) | 2014-02-11 | 2016-10-07 | Massachusetts Inst Technology | Novel full spectrum anti-dengue antibody. |
US20150252434A1 (en) | 2014-03-07 | 2015-09-10 | University Health Network | Methods and compositions for detection of targets involved in cancer metastasis |
EP3116907A1 (en) | 2014-03-12 | 2017-01-18 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
EP3116906A1 (en) | 2014-03-12 | 2017-01-18 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
MX2016012274A (en) | 2014-03-21 | 2017-05-23 | Regeneron Pharma | Non-human animals that make single domain binding proteins. |
US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
WO2015155694A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
EP3134439B1 (en) | 2014-04-21 | 2018-12-26 | Millennium Pharmaceuticals, Inc. | Anti-psyk antibody molecules and use of same for syk-targeted therapy |
KR20170040132A (en) * | 2014-06-02 | 2017-04-12 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | Production of fc fragments |
NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
JP6913018B2 (en) | 2014-07-08 | 2021-08-04 | ニューヨーク・ユニバーシティ | Tau imaging ligands, and their use in the diagnosis and treatment of tau disorders |
WO2018140026A1 (en) | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
CA2957128C (en) | 2014-08-15 | 2023-09-26 | Genexine, Inc. | Methods of treating cervical cancer |
EA038798B1 (en) | 2014-08-27 | 2021-10-21 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Anti-b7h3 antibodies and binded compounds and use |
FR3025515B1 (en) | 2014-09-05 | 2016-09-09 | Lab Francais Du Fractionnement | PROCESS FOR PURIFYING MONOCLONAL ANTIBODY |
BR112017005202A2 (en) | 2014-09-16 | 2017-12-12 | Symphogen As | anti-met antibodies and compositions |
AU2015327819B2 (en) | 2014-10-03 | 2021-07-01 | Massachusetts Institute Of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
MA40835A (en) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES |
MA40861A (en) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES |
TWI711631B (en) | 2015-01-28 | 2020-12-01 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
TWI781507B (en) | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
TWI786505B (en) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
US10988534B2 (en) | 2015-02-09 | 2021-04-27 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof |
CA2979976A1 (en) | 2015-03-17 | 2016-09-22 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
KR20180026659A (en) | 2015-03-18 | 2018-03-13 | 더 존스 홉킨스 유니버시티 | A novel monoclonal antibody inhibitor targeting the potassium channel KCNK9 |
CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
JP7008920B2 (en) | 2015-03-30 | 2022-01-25 | 武田薬品工業株式会社 | Plasma kallikrein inhibitor and its use to prevent hereditary angioedema attacks |
FR3034420A1 (en) | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | ANTI-CD303 MONOCLONAL ANTIBODIES |
FR3034419B1 (en) | 2015-04-02 | 2017-12-15 | Lab Francais Du Fractionnement | PROCESS FOR PURIFYING RECOMBINANT THERAPEUTIC PROTEIN FROM TRANSGENIC MILK |
WO2016207717A1 (en) | 2015-06-24 | 2016-12-29 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
US10287338B2 (en) | 2015-07-10 | 2019-05-14 | Miran NERSISSIAN | Factor VIII protein compositions and methods of treating of hemophilia A |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
JO3711B1 (en) | 2015-07-13 | 2021-01-31 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
EP3328429A4 (en) | 2015-07-31 | 2019-03-20 | The Research Institute at Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
JP6909203B2 (en) | 2015-08-03 | 2021-07-28 | バイオベラティブ セラピューティクス インコーポレイテッド | Factor IX fusion proteins and their production and usage |
JP6913078B2 (en) | 2015-08-13 | 2021-08-04 | ニューヨーク・ユニバーシティ | Antibody-based molecules specific for the shortened Asp421 epitope of tau, and their use in the diagnosis and treatment of tau dysfunction. |
WO2017027691A1 (en) | 2015-08-13 | 2017-02-16 | New York University | Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
ES2890073T3 (en) | 2015-08-25 | 2022-01-17 | Prothena Biosciences Ltd | Methods to detect phosphorylated alpha-synuclein |
AU2016332725A1 (en) | 2015-09-29 | 2018-03-22 | Celgene Corporation | PD-1 binding proteins and methods of use thereof |
WO2017066719A2 (en) | 2015-10-14 | 2017-04-20 | Research Institute At Nationwide Children's Hospital | Hu specific interfering agents |
EP3374390A1 (en) | 2015-11-13 | 2018-09-19 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
US20190169262A1 (en) | 2015-12-04 | 2019-06-06 | Board Of Regents, The University Of Texas System | Slc45a2 peptides for immunotherapy |
CN108602893A (en) | 2015-12-11 | 2018-09-28 | 戴埃克斯有限公司 | Inhibitors of plasma kallikrein and its purposes for the treatment of hereditary angioedema breaking-out |
JP7217630B2 (en) | 2016-02-01 | 2023-02-03 | バイオベラティブ セラピューティクス インコーポレイテッド | Optimized Factor VIII gene |
US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
CA3014013A1 (en) | 2016-02-12 | 2017-08-17 | Janssen Pharmaceutica Nv | Anti-vista (b7h5) antibodies |
WO2017147248A1 (en) | 2016-02-24 | 2017-08-31 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
KR20230111268A (en) | 2016-03-28 | 2023-07-25 | 인사이트 코포레이션 | Pyrrolotriazine compounds as tam inhibitors |
CA3019164A1 (en) | 2016-03-29 | 2017-10-05 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
AU2017259039A1 (en) | 2016-05-02 | 2018-10-11 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2017191560A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
EP3478715A2 (en) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2018007922A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
JP7017013B2 (en) | 2016-07-02 | 2022-02-08 | プロセナ バイオサイエンシーズ リミテッド | Anti-transthyretin antibody |
DK3482210T3 (en) | 2016-07-06 | 2021-07-12 | Prothena Biosciences Ltd | ASSAY FOR DETECTING TOTAL AND S129 PHOSPHORYLATED ALPHA SYNUCLEIN |
EP3878864A1 (en) | 2016-07-12 | 2021-09-15 | H. Lundbeck A/S | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
WO2018022479A1 (en) | 2016-07-25 | 2018-02-01 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
CA3031390A1 (en) | 2016-07-28 | 2018-02-01 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anti- immunoglobulin g aptamers and uses thereof |
EP3510046A4 (en) | 2016-09-07 | 2020-05-06 | The Regents of the University of California | Antibodies to oxidation-specific epitopes |
JP2019534859A (en) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Method for treating vitiligo using PD-1 binding protein |
EP3515944A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | Methods of treating immune disorders using pd-1 binding proteins |
MX2019003703A (en) | 2016-09-30 | 2020-08-13 | Janssen Biotech Inc | Safe and effective method of treating psoriasis with anti-il23 specific antibody. |
WO2018067474A1 (en) | 2016-10-03 | 2018-04-12 | Abbott Laboratories | Improved methods of assessing gfap status in patient samples |
JP2020500007A (en) | 2016-10-13 | 2020-01-09 | マサチューセッツ インスティテュート オブ テクノロジー | Antibodies that bind to Zika virus envelope proteins and uses thereof |
BR112018014281A2 (en) | 2016-11-15 | 2018-12-18 | H Lundbeck As | agents, uses and methods for the treatment of synucleinopathy |
US11208474B2 (en) | 2016-11-16 | 2021-12-28 | Janssen Biotech, Inc. | Method of treating psoriasis with anti-IL23 specific antibody |
FR3060394B1 (en) | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | COMBINATION OF ANTI-CD303 AND ANTI-AMHRII ANTIBODIES |
WO2018109213A1 (en) | 2016-12-16 | 2018-06-21 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Aptamers directed against a kappa light chain-containing protein and uses thereof |
EP3555127A1 (en) | 2016-12-16 | 2019-10-23 | H. Lundbeck A/S | Agents, uses and methods |
FR3060395B1 (en) | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | COMBINATION OF ANTI-CD303 AND ANTI-HER2 ANTIBODIES |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
EP3559029A2 (en) | 2016-12-23 | 2019-10-30 | Bristol-Myers Squibb Company | Design of therapeutic immunoglobulin g4 for improved bioanalytical and bioprocessing properties |
MA47205A (en) | 2017-01-04 | 2019-11-13 | H Lundbeck As | SPECIFIC ANTIBODIES OF HYPERPHOSPHORYLATED TAU PROTEIN TO TREAT EYE DISEASES |
AU2018206560A1 (en) | 2017-01-04 | 2019-07-18 | Research Institute At Nationwide Children's Hospital | Antibody fragments for the treatment of biofilm-related disorders |
AU2018206552A1 (en) | 2017-01-04 | 2019-07-18 | Research Institute At Nationwide Children's Hospital | DNABII vaccines and antibodies with enhanced activity |
US11773182B2 (en) | 2017-01-05 | 2023-10-03 | The Johns Hopkins University | Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA) |
WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
JP2020506916A (en) | 2017-01-30 | 2020-03-05 | ヤンセン バイオテツク,インコーポレーテツド | Anti-TNF antibodies, compositions and methods for the treatment of active psoriatic arthritis |
CA3051862A1 (en) | 2017-01-31 | 2018-08-09 | Bioverativ Therapeutics Inc. | Factor ix fusion proteins and methods of making and using same |
CA3052578A1 (en) | 2017-02-07 | 2018-08-16 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
US11746136B2 (en) | 2017-03-15 | 2023-09-05 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
FR3064007A1 (en) | 2017-03-20 | 2018-09-21 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | ANTIBODIES FOR THE TREATMENT OF CANCERS |
WO2018175942A1 (en) | 2017-03-23 | 2018-09-27 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
JOP20190227A1 (en) | 2017-03-31 | 2019-09-30 | Biogen Int Neuroscience Gmbh | Compositions and methods for treating synucleinopathies |
BR112019021612A2 (en) | 2017-04-15 | 2020-05-12 | Abbott Laboratories | METHODS TO ASSIST HYPERAGUTE DIAGNOSIS AND DETERMINATION OF CRANIENCEPHALIC TRAUMATISM IN A HUMAN INDIVIDUAL WITH THE USE OF EARLY BIOMARKERS |
US10877038B2 (en) | 2017-04-28 | 2020-12-29 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
CA3078725A1 (en) | 2017-05-25 | 2018-11-29 | Abbott Laboratories | Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers |
AU2018275235A1 (en) | 2017-05-30 | 2019-10-31 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers |
EA202090063A1 (en) | 2017-06-16 | 2020-04-03 | Бристоль-Мейерз Сквибб Компани | COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHIA |
CN110831965B (en) | 2017-06-21 | 2023-03-07 | 吉利德科学公司 | Multispecific antibodies targeting HIV GP120 and CD3 |
JP7454945B2 (en) | 2017-07-03 | 2024-03-25 | アボット・ラボラトリーズ | Improved method for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood |
CR20200076A (en) | 2017-07-14 | 2020-06-10 | Pfizer | Antibodies to madcam |
US10894833B2 (en) | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
EP3444275A1 (en) | 2017-08-16 | 2019-02-20 | Exiris S.r.l. | Monoclonal antibody anti-fgfr4 |
CA3073066A1 (en) | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
KR20200044066A (en) | 2017-08-22 | 2020-04-28 | 바이오젠 엠에이 인코포레이티드 | Pharmaceutical compositions and dosing regimens containing anti-alpha (V) beta (6) antibodies |
US10759865B2 (en) | 2017-08-22 | 2020-09-01 | Eyal Levit | Treatment of diabetes mellitus |
TW201922780A (en) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | Safe and effective method of treating Lupus with anti-IL12/IL23 antibody |
WO2019094595A2 (en) | 2017-11-09 | 2019-05-16 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
EP3710474A1 (en) | 2017-11-14 | 2020-09-23 | Bio-Sourcing S.A. | Antibody purification |
WO2019113525A2 (en) | 2017-12-09 | 2019-06-13 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1) |
AU2018378084A1 (en) | 2017-12-09 | 2020-05-14 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1 |
FR3076294B1 (en) | 2017-12-29 | 2022-01-28 | Lab Francais Du Fractionnement | METHOD FOR PURIFYING ANTIBODIES FROM RAW MILK |
CA3084064A1 (en) | 2017-12-29 | 2019-07-04 | Abbott Laboratories | Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury |
WO2019150309A1 (en) | 2018-02-02 | 2019-08-08 | Hammack Scott | Modulators of gpr68 and uses thereof for treating and preventing diseases |
CA3089211A1 (en) | 2018-02-06 | 2019-08-15 | Ablynx Nv | Methods of treating initial episode of ttp with immunoglobulin single variable domains |
TW202000666A (en) | 2018-02-27 | 2020-01-01 | 美商英塞特公司 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
IL310216A (en) | 2018-03-05 | 2024-03-01 | Janssen Biotech Inc | Methods of treating crohn's disease with anti-il23 specific antibody |
BR112020018560A2 (en) | 2018-03-12 | 2020-12-29 | Memorial Sloan Kettering Cancer Center | SPECIFIC BI CONNECTION AGENTS AND USES OF THE SAME |
EP3788377A1 (en) | 2018-05-04 | 2021-03-10 | Abbott Laboratories | Hbv diagnostic, prognostic, and therapeutic methods and products |
WO2019217455A1 (en) | 2018-05-07 | 2019-11-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
EP3790584A4 (en) | 2018-05-07 | 2022-03-30 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
MA52590A (en) | 2018-05-11 | 2021-03-17 | Janssen Biotech Inc | METHODS OF TREATING DEPRESSION USING IL-23 ANTIBODIES |
CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
KR20210027352A (en) | 2018-06-04 | 2021-03-10 | 바이오젠 엠에이 인코포레이티드 | Anti-VLA-4 antibody with reduced effector function |
AU2019288276A1 (en) | 2018-06-20 | 2021-01-14 | Incyte Corporation | Anti-PD-1 antibodies and uses thereof |
TW202016144A (en) | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | Compositions including cd3 antigen binding fragments and uses thereof |
AR117600A1 (en) | 2018-06-29 | 2021-08-18 | Incyte Corp | FORMULATIONS OF AN AXL / MER INHIBITOR |
EP4257600A3 (en) | 2018-07-03 | 2024-01-10 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
WO2020016838A2 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
US11548938B2 (en) | 2018-08-21 | 2023-01-10 | Quidel Corporation | DbpA antibodies and uses thereof |
AU2019328324A1 (en) | 2018-08-30 | 2021-04-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
LT3883606T (en) | 2018-09-24 | 2023-09-11 | Janssen Biotech, Inc. | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
CN113056480A (en) | 2018-10-04 | 2021-06-29 | 乔治-奥古斯特-哥廷根大学公法大学医学基金会 | Humanized anti-N truncated amyloid beta monoclonal antibody |
JP2022512580A (en) | 2018-10-05 | 2022-02-07 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Compositions and Methods for Enzymatic Destruction of Bacterial Biofilms |
TW202034958A (en) | 2018-10-30 | 2020-10-01 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate |
MA55149A (en) | 2018-11-20 | 2021-09-29 | Janssen Biotech Inc | SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY |
CN113194991A (en) | 2018-11-26 | 2021-07-30 | 四十七公司 | Humanized antibodies to C-KIT |
GB201820006D0 (en) | 2018-12-07 | 2019-01-23 | Lifearc | Humanised anti-IL17BR antibody |
US20200197517A1 (en) | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody |
KR20210116540A (en) | 2019-01-15 | 2021-09-27 | 얀센 바이오테크 인코포레이티드 | Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis |
US20220064278A1 (en) | 2019-01-23 | 2022-03-03 | Janssen Biotech, Inc. | Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis |
TWI829857B (en) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors |
SG11202108414UA (en) | 2019-03-03 | 2021-08-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
WO2020185069A1 (en) | 2019-03-08 | 2020-09-17 | Linxis B.V. | Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation |
US20220144945A1 (en) | 2019-03-11 | 2022-05-12 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-lingo-1 antibodies |
EA202192505A1 (en) | 2019-03-14 | 2022-03-29 | Янссен Байотек, Инк. | METHODS FOR OBTAINING COMPOSITIONS OF ANTIBODIES TO TNF |
MA55282A (en) | 2019-03-14 | 2022-01-19 | Janssen Biotech Inc | MANUFACTURING METHODS FOR THE PRODUCTION OF ANTI-TNF ANTIBODY COMPOSITIONS |
TW202100561A (en) | 2019-03-14 | 2021-01-01 | 美商戴氏公司 | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
CN113825765A (en) | 2019-03-14 | 2021-12-21 | 詹森生物科技公司 | Method for producing anti-IL 12/IL23 antibody composition |
US20220153829A1 (en) | 2019-03-14 | 2022-05-19 | Janssen Biotech, Inc. | Methods for Producing Anti-TNF Antibody Compositions |
US20200331996A1 (en) | 2019-03-18 | 2020-10-22 | Janssen Biotech, Inc. | Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody |
CN113924147A (en) | 2019-03-25 | 2022-01-11 | 威特拉公司 | Compositions and methods for treating and preventing influenza |
MA55613A (en) | 2019-04-08 | 2022-02-16 | Biogen Ma Inc | ANTI-INTEGRIN ANTIBODIES AND THEIR USES |
WO2020234834A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
MX2021014885A (en) | 2019-06-03 | 2022-04-06 | Janssen Biotech Inc | Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis. |
EP3976183A1 (en) | 2019-06-03 | 2022-04-06 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
JP7295283B2 (en) | 2019-06-25 | 2023-06-20 | ギリアード サイエンシーズ, インコーポレイテッド | FLT3L-FC fusion proteins and methods of use |
CN114401986A (en) | 2019-07-08 | 2022-04-26 | 国家儿童医院研究所 | Antibody composition for disrupting biological membranes |
CA3148776A1 (en) | 2019-08-01 | 2021-02-04 | Incyte Corporation | A dosing regimen for an ido inhibitor |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
MX2022005240A (en) | 2019-11-04 | 2022-08-19 | Seagen Inc | Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection. |
MX2022005222A (en) | 2019-11-07 | 2022-06-08 | Genmab As | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate. |
TW202131954A (en) | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate |
US20230028476A1 (en) | 2019-12-03 | 2023-01-26 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use in treating hepatitis b infection |
IL293450A (en) | 2019-12-03 | 2022-07-01 | Evotec Int Gmbh | Interferon-associated antigen binding proteins and uses thereof |
US20230257449A1 (en) | 2019-12-11 | 2023-08-17 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
CN115298213A (en) | 2019-12-19 | 2022-11-04 | 奎多公司 | Monoclonal antibody fusion |
AU2020419293A1 (en) | 2020-01-03 | 2022-07-28 | Incyte Corporation | CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy |
CA3166549A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors |
PE20221409A1 (en) | 2020-01-03 | 2022-09-20 | Incyte Corp | ANTI-CD73 ANTIBODIES AND THEIR USES |
WO2021146160A1 (en) | 2020-01-13 | 2021-07-22 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
AU2021230385A1 (en) | 2020-03-06 | 2022-09-22 | Incyte Corporation | Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors |
WO2021202948A2 (en) | 2020-04-04 | 2021-10-07 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
WO2021211331A1 (en) | 2020-04-13 | 2021-10-21 | Abbott Point Of Care Inc. | METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE |
CA3176240A1 (en) | 2020-04-24 | 2021-10-28 | Young Chul Sung | Method for treating cervical cancer |
US20230167198A1 (en) | 2020-04-27 | 2023-06-01 | The Regents Of The University Of California | Isoform-independent antibodies to lipoprotein(a) |
EP3909601A1 (en) | 2020-05-11 | 2021-11-17 | LeukoCom GmbH | A novel antibody binding specifically to human ceacam1/3/5 and use thereof |
AU2021299947A1 (en) | 2020-06-29 | 2022-12-22 | Genmab A/S | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
IT202000015754A1 (en) | 2020-06-30 | 2021-12-30 | Fond Toscana Life Sciences | ANTIBODIES TO CORONAVIRUS |
EP4175982A1 (en) | 2020-06-30 | 2023-05-10 | Fondazione Toscana Life Sciences | Neutralizing antibodies to sars coronavirus-2 |
CA3188349A1 (en) | 2020-08-04 | 2022-02-10 | A. Scott Muerhoff | Improved methods and kits for detecting sars-cov-2 protein in a sample |
JP2023541934A (en) | 2020-09-16 | 2023-10-04 | リンクシス ベスローテン フェンノートシャップ | internalized binding molecules |
TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
CA3200671A1 (en) | 2020-11-17 | 2022-05-27 | Seagen Inc. | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody |
TW202241436A (en) | 2020-11-30 | 2022-11-01 | 美商英塞特公司 | Combination therapy with an anti-cd19 antibody and parsaclisib |
WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
WO2022119841A1 (en) | 2020-12-01 | 2022-06-09 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
KR20230157940A (en) | 2020-12-29 | 2023-11-17 | 인사이트 코포레이션 | Combination therapy comprising A2A/A2B inhibitors, PD-1/PD-L1 inhibitors and anti-CD73 antibodies |
WO2022147147A1 (en) | 2020-12-30 | 2022-07-07 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
WO2022153194A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
KR20230146522A (en) | 2021-01-13 | 2023-10-19 | 메모리얼 슬로안 케터링 캔서 센터 | Anti-DLL3 antibody-drug conjugate |
IL303969A (en) | 2021-01-24 | 2023-08-01 | David Forrest Michael | Bnjm |
KR20230156764A (en) | 2021-03-12 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | Method for treating psoriatic arthritis patients with inadequate response to TNF therapy by anti-IL23 specific antibody |
CA3212729A1 (en) | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
GB202105110D0 (en) | 2021-04-09 | 2021-05-26 | Cancer Research Tech Ltd | Anti-CD73 antibodies |
AU2022279156A1 (en) | 2021-05-18 | 2023-11-02 | Abbott Laboratories | Methods of evaluating brain injury in a pediatric subject |
US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
IL308607A (en) | 2021-05-20 | 2024-01-01 | Janssen Biotech Inc | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
TW202313098A (en) | 2021-06-09 | 2023-04-01 | 德商埃沃特克國際有限公司 | Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection |
CA3222291A1 (en) | 2021-06-14 | 2022-12-22 | Jaime MARINO | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
WO2023283345A1 (en) | 2021-07-07 | 2023-01-12 | Incyte Corporation | Anti-b7-h4 antibodies and uses thereof |
US20230040065A1 (en) | 2021-07-09 | 2023-02-09 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
US20230042465A1 (en) | 2021-07-09 | 2023-02-09 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
US20230038355A1 (en) | 2021-07-09 | 2023-02-09 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions |
AR126846A1 (en) | 2021-08-23 | 2023-11-22 | Bioverativ Therapeutics Inc | OPTIMIZED FACTOR VIII GENES |
WO2023028455A1 (en) | 2021-08-23 | 2023-03-02 | Bioverativ Therapeutics Inc. | Closed-end dna production with inverted terminal repeat sequences |
WO2023028186A1 (en) | 2021-08-27 | 2023-03-02 | Abbott Laboratories | Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample |
WO2023034777A1 (en) | 2021-08-31 | 2023-03-09 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
TW202346327A (en) | 2021-09-30 | 2023-12-01 | 美商百歐維拉提夫治療公司 | Nucleic acids encoding factor viii polypeptides with reduced immunogenicity |
CA3232176A1 (en) | 2021-09-30 | 2023-04-06 | Beth MCQUISTON | Methods and systems of diagnosing brain injury |
AU2022377628A1 (en) | 2021-10-29 | 2024-04-11 | Seagen Inc. | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate |
WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
US20230151087A1 (en) | 2021-11-15 | 2023-05-18 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
WO2023095000A1 (en) | 2021-11-23 | 2023-06-01 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
WO2023094980A1 (en) | 2021-11-23 | 2023-06-01 | Fondazione Toscana Life Sciences | Antibodies to coronavirus |
TW202330623A (en) | 2021-12-08 | 2023-08-01 | 美商英塞特公司 | Anti-mutant calreticulin (calr) antibodies and uses thereof |
WO2023114978A1 (en) | 2021-12-17 | 2023-06-22 | Abbott Laboratories | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
CA3223956A1 (en) | 2021-12-20 | 2023-06-29 | Vetoquinol Sa | Anti-canine interleukine-31-receptor a (il-31ra) antibodies and the uses thereof |
TW202334231A (en) | 2021-12-22 | 2023-09-01 | 德商莫菲西斯公司 | Treatment paradigm for an anti-cd19 antibody therapy |
WO2023129942A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
WO2023131901A1 (en) | 2022-01-07 | 2023-07-13 | Johnson & Johnson Enterprise Innovation Inc. | Materials and methods of il-1beta binding proteins |
WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
US20230312703A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of Treating Psoriasis with IL-23 Specific Antibody |
WO2023213960A1 (en) | 2022-05-06 | 2023-11-09 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
WO2023223265A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
WO2024028731A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Transferrin receptor binding proteins for treating brain tumors |
WO2024028732A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Cd98 binding constructs for treating brain tumors |
WO2024036265A2 (en) | 2022-08-12 | 2024-02-15 | Takeda Vaccines, Inc. | Novel anti-denv3 antibodies |
WO2024059708A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury |
WO2024059692A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Hbv diagnostic, prognostic, and therapeutic methods and products |
US20240101718A1 (en) | 2022-09-28 | 2024-03-28 | Incyte Corporation | Anti-pd-1/lag-3 bispecific antibodies and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824837A (en) * | 1993-07-22 | 1998-10-20 | Merck & Co., Inc. | Expression of human interleukin-1β in a transgenic animal |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5366894A (en) * | 1986-06-30 | 1994-11-22 | Pharmaceutical Proteins Limited | Peptide production |
GB8615942D0 (en) * | 1986-06-30 | 1986-08-06 | Animal & Food Research Council | Peptide production |
EP0832981A1 (en) * | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
EP0502976B1 (en) * | 1989-12-01 | 1996-07-03 | Pharming B.V. | Production of recombinant polypeptides by bovine species and transgenic methods |
DE4000939A1 (en) * | 1990-01-15 | 1991-07-18 | Brem Gottfried Prof Dr Dr | METHOD FOR OBTAINING ANTIBODIES |
ES2108048T3 (en) * | 1990-08-29 | 1997-12-16 | Genpharm Int | PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
EP0746609A4 (en) * | 1991-12-17 | 1997-12-17 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
-
1993
- 1993-12-20 US US08/170,579 patent/US5827690A/en not_active Expired - Lifetime
-
1994
- 1994-12-20 CA CA2178941A patent/CA2178941C/en not_active Expired - Lifetime
- 1994-12-20 NZ NZ278744A patent/NZ278744A/en not_active IP Right Cessation
- 1994-12-20 DE DE69433325T patent/DE69433325T2/en not_active Expired - Lifetime
- 1994-12-20 PT PT95906691T patent/PT741515E/en unknown
- 1994-12-20 EP EP95906691A patent/EP0741515B1/en not_active Expired - Lifetime
- 1994-12-20 AU AU15172/95A patent/AU688845B2/en not_active Ceased
- 1994-12-20 AT AT95906691T patent/ATE253817T1/en not_active IP Right Cessation
- 1994-12-20 JP JP51760295A patent/JP3970923B2/en not_active Expired - Lifetime
- 1994-12-20 WO PCT/US1994/014795 patent/WO1995017085A1/en active IP Right Grant
- 1994-12-20 EP EP03077751A patent/EP1400171A1/en not_active Withdrawn
- 1994-12-20 DK DK95906691T patent/DK0741515T3/en active
- 1994-12-20 ES ES95906691T patent/ES2210281T3/en not_active Expired - Lifetime
-
1995
- 1995-03-27 US US08/410,887 patent/US5849992A/en not_active Expired - Lifetime
-
1998
- 1998-01-23 US US09/012,904 patent/US20040006776A1/en not_active Abandoned
- 1998-06-19 AU AU73079/98A patent/AU7307998A/en not_active Abandoned
-
2006
- 2006-10-04 JP JP2006273219A patent/JP2007006900A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824837A (en) * | 1993-07-22 | 1998-10-20 | Merck & Co., Inc. | Expression of human interleukin-1β in a transgenic animal |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7939317B1 (en) | 1986-04-09 | 2011-05-10 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
US20060179500A1 (en) * | 1998-06-19 | 2006-08-10 | Gtc-Biotherapeutics, Inc. | Methods and vectors for improving nucleic acid expression |
US20040226052A1 (en) * | 2000-10-13 | 2004-11-11 | Meade Harry M. | Methods of producing a target molecule in a transgenic animal and purification of the target molecule |
US20040226053A1 (en) * | 2000-10-13 | 2004-11-11 | Meade Harry M. | Methods of producing a target molecule in a transgenic animal and purification of the target molecule |
US20080235813A1 (en) * | 2002-06-26 | 2008-09-25 | Cooper Richard K | Gene regulation in transgenic animals using a transposon-based vector |
US20040197910A1 (en) * | 2002-06-26 | 2004-10-07 | Cooper Richard K. | Gene regulation in transgenic animals using a transposon-based vector |
US20080235815A1 (en) * | 2002-06-26 | 2008-09-25 | Cooper Richard K | Administration of transposon-based vectors to reproductive organs |
US20040172667A1 (en) * | 2002-06-26 | 2004-09-02 | Cooper Richard K. | Administration of transposon-based vectors to reproductive organs |
US8283518B2 (en) | 2002-06-26 | 2012-10-09 | Transgenrx, Inc. | Administration of transposon-based vectors to reproductive organs |
US8236294B2 (en) | 2003-12-24 | 2012-08-07 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Gene therapy using transposon-based vectors |
US20100199366A1 (en) * | 2003-12-24 | 2010-08-05 | Richard Cooper | Gene therapy using transposon-based vectors |
US8071364B2 (en) | 2003-12-24 | 2011-12-06 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
US20110104049A1 (en) * | 2005-02-15 | 2011-05-05 | Gtc Biotherapeutics, Inc. | Method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
US20080118501A1 (en) * | 2005-10-21 | 2008-05-22 | Gtc Biotherapeutics, Inc. | Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use |
US20110229460A1 (en) * | 2008-05-01 | 2011-09-22 | Gtc Biotherapeutics, Inc. | anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
US20100081789A1 (en) * | 2008-09-25 | 2010-04-01 | Cooper Richard K | Novel Vectors for Production of Interferon |
US9157097B2 (en) | 2008-09-25 | 2015-10-13 | Proteovec Holding, L.L.C. | Vectors for production of growth hormone |
US20100099148A1 (en) * | 2008-09-25 | 2010-04-22 | Cooper Richard K | Novel Vectors for Production of Antibodies |
US20100093036A1 (en) * | 2008-09-25 | 2010-04-15 | Cooper Richard K | Novel Vectors for Production of Growth Hormone |
US9150880B2 (en) | 2008-09-25 | 2015-10-06 | Proteovec Holding, L.L.C. | Vectors for production of antibodies |
US20170163823A1 (en) * | 2009-01-28 | 2017-06-08 | Sharp Kabushiki Kaisha | Image forming apparatus, image printing method, external device, recording medium and communication system |
US9150881B2 (en) | 2009-04-09 | 2015-10-06 | Proteovec Holding, L.L.C. | Production of proteins using transposon-based vectors |
US20100261227A1 (en) * | 2009-04-09 | 2010-10-14 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Production of Proteins Using Transposon-Based Vectors |
US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
USRE49339E1 (en) | 2010-06-22 | 2022-12-20 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3D fragment of complement component 3 |
US11553712B2 (en) | 2010-12-30 | 2023-01-17 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Glycols as pathogen inactivating agents |
US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
US10174110B2 (en) | 2013-02-13 | 2019-01-08 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-TNF-α antibodies and uses thereof |
US10611826B2 (en) | 2013-07-05 | 2020-04-07 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Affinity chromatography matrix |
Also Published As
Publication number | Publication date |
---|---|
JP3970923B2 (en) | 2007-09-05 |
AU1517295A (en) | 1995-07-10 |
DK0741515T3 (en) | 2004-03-08 |
DE69433325D1 (en) | 2003-12-18 |
ATE253817T1 (en) | 2003-11-15 |
PT741515E (en) | 2004-03-31 |
EP0741515A4 (en) | 1998-05-27 |
US5849992A (en) | 1998-12-15 |
WO1995017085A1 (en) | 1995-06-29 |
ES2210281T3 (en) | 2004-07-01 |
JPH09506779A (en) | 1997-07-08 |
DE69433325T2 (en) | 2004-09-16 |
CA2178941C (en) | 2010-10-26 |
EP0741515B1 (en) | 2003-11-12 |
JP2007006900A (en) | 2007-01-18 |
AU688845B2 (en) | 1998-03-19 |
EP1400171A1 (en) | 2004-03-24 |
NZ278744A (en) | 1997-04-24 |
EP0741515A1 (en) | 1996-11-13 |
US5827690A (en) | 1998-10-27 |
AU7307998A (en) | 1998-08-20 |
CA2178941A1 (en) | 1995-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5849992A (en) | Transgenic production of antibodies in milk | |
JP3068506B2 (en) | Generation of heterologous antibodies | |
AU2001284703B2 (en) | Production of humanized antibodies in transgenic animals | |
JP2014121337A (en) | C1 inhibitor produced in milk of transgenic mammals | |
US8173860B2 (en) | Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion | |
JP2006507839A (en) | Modified antibody stably produced in milk and method for producing the same | |
US20040092719A1 (en) | Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds | |
AU2003248473B2 (en) | Transgenic production of antibodies in milk | |
AU2007205719A1 (en) | Transgenic production of antibodies in milk | |
WO2020053661A1 (en) | Methods of purifying antibodies from the milk of transgenic non-human mammals comprising the use of chitosan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GTC BIOTHERAPEUTICS, INC., MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:GENZYME TRANSGENICS CORPORATION;REEL/FRAME:013782/0450 Effective date: 20020522 |
|
AS | Assignment |
Owner name: LFB BIOTECHNOLOGIES S.A.S.U., FRANCE Free format text: SECURITY AGREEMENT;ASSIGNOR:GTC BIOTHERAPEUTICS, INC.;REEL/FRAME:022019/0205 Effective date: 20081219 |
|
AS | Assignment |
Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, CONNECTICUT Free format text: SECURITY AGREEMENT;ASSIGNOR:GTC BIOTHERAPEUTICS, INC.;REEL/FRAME:022119/0854 Effective date: 20081222 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: GTC BIOTHERAPEUTICS, INC., MASSACHUSETTS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION;REEL/FRAME:032424/0230 Effective date: 20140311 |
|
AS | Assignment |
Owner name: GTC BIOTHERAPEUTICS, INC., MASSACHUSETTS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:LFB BIOTECHNOLOGIES S.A.S.U.;REEL/FRAME:032448/0045 Effective date: 20140311 |